世界卫生组织

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Ref.: C.L.9.2018

世界卫生组织谨此致意，并荣幸地根据执行委员会以 EB15.R7[1]号决议通过的“选择推荐的国际非专利药品名称程序”第 3.A 和 7 条的要求，送去一份经世界卫生组织推荐并且已经发表作为国际非专利名称的名称清单（缩写为 Rec. INN）。

… 根据上述程序第 8 条要求，世界卫生组织要求所附名称清单*被认定为相关药物的非专利名称，同时要求采取必要措施防止使这些名称得到专利权，包括禁止将这些名称注册为商标或贸易名称。

2018 年 3 月 27 日于日内瓦

[1] EB15.R7 号决议附件，世界卫生组织正式记录，第 60 期，第 3 及第 55 页。EB43.R9 号决议对此案文作出了修订，世界卫生组织正式记录，第 173 期，第 10 页以及 EB115.R4 号决议，执行委员会第 115 届会议决议和决定（EB115/2005/REC/1），第 2 页。

… 内附：(1)* *Rec. INN*：世卫组织药品信息刊登的清单 79，第 32 卷，第 1 期，2018 年。

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 79

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–117) and Recommended (1–78) International Nonproprietary Names can be found in *Cumulative List No. 17, 2017* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 79

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–117) et recommandées (1–78) dans la *Liste récapitulative No. 17, 2017* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 79

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–117) y Recomendadas (1–78) se encuentran reunidas en *Cumulative List No. 17, 2017* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN* *DCI Recommandée* *DCI Recomendada*	*Chemical name or description; Molecular formula; Graphic formula* *Nom chimique ou description; Formule brute; Formule développée* *Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

adafosbuvirum

adafosbuvir — propan-2-yl *N*-[(*P*$^{5'}$*S*)-4'-fluoro-2'-*C*-methyl-*P*-*O*-phenyl-5'-uridylyl]-L-alaninate

adafosbuvir — *N*-[(*P*$^{5'}$*S*)-4'-fluoro-2'-*C*-méthyl-*P*-*O*-phényl-5'-uridylyl]-L-alaninate de propan-2-yle

adafosbuvir — *N*-[(*P*$^{5'}$*S*)-4'-fluoro-2'-*C*-metil-*P*-*O*-fenil-5'-uridilil]-L-alaninato de propan-2-ilo

$C_{22}H_{29}FN_3O_{10}P$



adarigilinum

adarigiline — (4-hydroxypiperidin-1-yl){5-[4-methyl-5-(trifluoromethyl)-1,2-oxazol-3-yl]thiophen-2-yl}methanone

adarigiline — (4-hydroxypipéridin-1-yl){5-[4-méthyl-5-(trifluorométhyl)-1,2-oxazol-3-yl]thiophén-2-yl}methanone

adarigilina — (4-hidroxipiperidin-1-il){5-[4-metil-5-(trifluoromethil)-1,2-oxazol-3-il]tiofeno-2-il}metanona

$C_{15}H_{15}F_3N_2O_3S$



adavosertibum

adavosertib — 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib — 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-méthylpipérazin-1-yl)anilino]-2-(prop-2-én-1-yl)-1,2-dihydro-3*H*-pyrazolo[3,4-*d*]pyrimidin-3-one

adavosertib — 1-[6-(2-hidroxipropan-2-il)piridin-2-il]-6-[4-(4-metilpiperazin-1-il)anilino]-2-(prop-2-en-1-il)-1,2-dihidro-3*H*-pirazolo[3,4-*d*]pirimidin-3-ona

$C_{27}H_{32}N_8O_2$



adimlecleucelum

adimlecleucel — Human culture enriched allogenic Cytomegalovirus-specific cytotoxic T cells (CMV-CTL) for cell-based therapy. Cells are isolated from blood of CMV seropositive healthy human donors. CMV-CTLs exhibit human leukocyte antigen (HLA)-restricted cytotoxic activity against CMV+ cells in allogeneic hematopoietic cell or solid organ transplant patients with CMV infection.

adimlecleucel — Lymphocytes T cytotoxiques spécifiques du cytomégalovirus (CMV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs au CMV. Les CMV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules CMV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques ou avec un organe solide, et souffrants d'une infection à CMV.

adimlecleucel — Linfocitos T citotóxicos específicos del virus de Citomegalovirus (CMV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están asiladas a partir de sangre de donantes humanos sanos seropositivo para CMV. Los CMV-CTLs muestran actividad citotóxica restringida por HLA contra células CMV+ en pacientes trasplantados con células hematopoyéticas alogénicas u órgano sólido con infección por CMV.

alirinetidum

alirinetide — L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinétide — L-phénylalanyl-L-séryl-L-arginyl-L-tyrosyl-L-alanyl-L-arginine

alirinetida — L-fenilalanil-L-seril-L-arginil-L-tirosil-L-alanil-L-arginina

$C_{36}H_{54}N_{12}O_9$

H–Phe–Ser–Arg–Tyr–Ala–Arg–OH

alobresibum

alobresib — [2-cyclopropyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)methanol

alobrésib — [2-cyclopropyl-6-(3,5-diméthyl-1,2-oxazol-4-yl)-1*H*-benzimidazol-4-yl]di(pyridin-2-yl)méthanol

alobresib — [2-ciclopropil-6-(3,5-dimetil-1,2-oxazol-4-il)-1*H*-benzimidazol-4-il]di(piridin-2-il)metanol

$C_{26}H_{23}N_5O_2$



arfolitixorinum

arfolitixorin — *N*-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-*f*]pteridin-8(9*H*)-yl]benzoyl}-L-glutamic acid

arfolitixorine — acide *N*-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-*f*]ptéridin-8(9*H*)-yl]benzoyl}-L-glutamique

arfolitixorina — ácido *N*-{4-[(6a*R*)-3-amino-1-oxo-1,2,5,6,6a,7-hexahidroimidazo[1,5-*f*]pteridin-8(9*H*)-il]benzoil}-L-glutámico

$C_{20}H_{23}N_7O_6$



asivatrepum

asivatrep — (2*E*)-*N*-{(1*R*)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl}-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide

asivatrep — (2*E*)-*N*-{(1*R*)-1-[3,5-difluoro-4-(méthanesulfonamido)phényl]éthyl}-3-[2-propyl-6-(trifluorométhyl)pyridin-3-yl]prop-2-énamide

asivatrep — (2*E*)-*N*-{(1*R*)-1-[3,5-difluoro-4-(metanosulfonamido)fenil]etil}-3-[2-propil-6-(trifluorometil)piridin-3-il]prop-2-enamida

$C_{21}H_{22}F_5N_3O_3S$



atabecestatum

atabecestat — *N*-{3-[(4*S*)-2-amino-4-methyl-4*H*-1,3-thiazin-4-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide

atabécestat — *N*-{3-[(4*S*)-2-amino-4-méthyl-4*H*-1,3-thiazin-4-yl]-4-fluorophényl}-5-cyanopyridine-2-carboxamide

atabecestat — *N*-{3-[(4*S*)-2-amino-4-metil-4*H*-1,3-tiazin-4-il]-4-fluorofenil}-5-cianopiridina-2-carboxamida

$C_{18}H_{14}FN_5OS$



atidortoxumabum #

atidortoxumab — immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* alpha toxin (AT, alpha-hemolysin, alpha-HL, hly, hla) and bi-component leukocidins (HlgAB, HlgCB, LukED, and LukSF (Panton-Valentine leukocidin, PVL)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228":231-231")-bisdisulfide

atidortoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* toxine alpha (AT, hémolysine alpha, HL-alpha, hly, hla) et leucocidines à deux composants (HlgAB, HlgCB, LukED, LukSF (leucocidine de Panton-Valentine, PVL)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure

atidortoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* toxina alfa (AT, hemolisina alfa, HL-alfa, hly, hla) y leucocidinas con dos componentes (HlgAB, HlgCB, LukED, LukSF (Panton-Valentine leukocidina, PVL)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-38-2*01 (92.90%) -(IGHD) -IGHJ6*03) [9.7.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQESGPG LVRPSETLSL TCAVSGYSIS SGMGWGWIRQ PPGKGLEWIG  50
SIDQRGSTYY NPSLKSRVTI SVDTSKNQFS LKLSSVTAAD TAVYYCARDA 100
GHAVDMDVWG KGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT ITCRASQGIS RWLAWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GYVFPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22''-96'' 146''-202'' 263''-323'' 369''-427''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 222-214' 222''-214'''
Inter-H-H (h 11, h 14) 228-228'' 231-231''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
G0F 46%, G1F 39.9%

avadomidum

avadomide — *rac*-(3*R*)-3-(5-amino-2-methyl-4-oxoquinazolin-3(4*H*)-yl)piperidine-2,6-dione

avadomide — *rac*-(3*R*)-3-(5-amino-2-méthyl-4-oxoquinazolin-3(4*H*)-yl)pipéridine-2,6-dione

avadomida — *rac*-(3*R*)-3-(5-amino-2-metil-4-oxoquinazolin-3(4*H*)-il)piperidina-2,6-diona

$C_{14}H_{14}N_4O_3$



avalglucosidasum alfa #

avalglucosidase alfa — mutated human acid α-glucosidase produced in Chinese hamster ovary (CHO) cells, glycoform alfa, conjugated to a synthetic branched hexasaccharide containing two terminal mannose-6-phosphate (M6P), via aminooxy linkers;

[His^{143}>Arg,Arg^{167}>His,Val^{724}>Ile]prepro-lysosomal α-glucosidase (EC=3.2.1.20) (human) (57-952)-peptide, expressed in CHO cells, glycoform alfa, with 5~9 sialyl end groups of glycan residues being oxidized and chemically modified to 5-acetamido-3,5,7-trideoxy-7-[(*E*)-(2-oxo-2-{2-[4-({*O*-(6-*O*-phosphono-α-D-mannopyranosyl)-(1→2)-*O*-α-D-mannopyranosyl-(1→6)-*O*-α-D-mannopyranosyl-(1→6)-*O*-[*O*-(6-*O*-phosphono-α-D-mannopyranosyl)-(1→2)-*O*-α-D-mannopyranosyl-(1→3)]-β-D-mannopyranosyl}oxy)butanoyl]hydrazinyl}ethoxy)imino]-β-L-*arabino*-2-heptulo-2,6-pyranosylonic acid groups

avalglucosidase alfa — α-glucosidase acide humaine modifiée, produite dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa, liée à un hexasaccharide de synthèse dont les résidus terminaux sont deux mannose-6-phosphates via un groupe aminoxy;

[His^{143}>Arg,Arg^{167}>His,Val^{724}>Ile]prépro-α-glucosidase lysosomale (EC=3.2.1.20) (humaine) (57-952)-peptide, exprimé dans des cellules CHO, glycoforme alfa: 5~9 résidus sialyl terminaux sont oxidés et chimiquement modifiés en acide 5-acétamido-3,5,7-tridésoxy-7-[(*E*)-(2-oxo-2-{2-[4-({*O*-(6-*O*-phosphono-α-D-mannopyranosyl)-(1→2)-*O*-α-D-mannopyranosyl-(1→6)-*O*-α-D-mannopyranosyl-(1→6)-*O*-[*O*-(6-*O*-phosphono-α-D-mannopyranosyl)-(1→2)-*O*-α-D-mannopyranosyl-(1→3)]-β-D-mannopyranosyl}oxy)butanoyl]hydrazinyl}éthoxy)imino]-β-L-*arabino*-2-heptulo-2,6-pyranosylonique

avalglucosidasa alfa

α-glucosidasa ácida humana modificada, producida en las células ováricas de hamster chino (CHO), glicoforma alfa, conjugada con un glicano hexasacarídico sintético que contiene dos manosa-6-fosfatos (M6Ps) terminales, vía un grupo aminoxi;

[His^{143}>Arg,Arg^{167}>His,Val^{724}>Ile]prepro-α-glucosidasa lisosomal (EC=3.2.1.20) (humana) (57-952)-péptido, expresada en las células CHO, glicoforma alfa: con los 5~9 restos sialil terminales están oxidados y químicamente modificados en ácido 5-acetamido-3,5,7-tridesoxi-7-[(*E*)-(2-oxo-2-{2-[4-({*O*-(6-*O*-fosfono-α-D-manopiranosil)-(1→2)-*O*-α-D-manopiranosil-(1→6)-*O*-α-D-manopiranosil-(1→6)-*O*-[*O*-(6-*O*-fosfono-α-D-manopiranosil)-(1→2)-*O*-α-D-manopiranosil-(1→3)]-β-D-manopiranosil}oxi)butanoil]hidrazinil}etoxi)imino]-β-L-*arabino*-2-heptulo-2,6-piranosilónico

Sequence / Séquence / Secuencia

```
QQGASRPGPR DAQAHPGRPR AVPTQCDVPP NSRFDCAPDK AITQEQCEAR  50
GCCYIPAKQG LQGAQMGQPW CFFPPSYPSY KLENLSSSEM GYTATLTRTT 100
PTFFPKDILT LRLDVMMETE NRLHFTIKDP ANRRYEVPLE TPRVHSRAPS 150
PLYSVEFSEE PFGVIVHRQL DGRVLLNTTV APLFFADQFL QLSTSLPSQY 200
ITGLAEHLSP LMLSTSWTRI TLWNRDLAPT PGANLYGSHP FYLALEDGGS 250
AHGVFLLNSN AMDVVLQPSP ALSWRSTGGI LDVYIFLGPE PKSVVQQYLD 300
VVGYPFMPPY WGLGFHLCRW GYSSTAITRQ VVENMTRAHF PLDVQWNDLD 350
YMDSRRDFTF NKDGFRDFPA MVQELHQGGR RYMMIVDPAI SSSGPAGSYR 400
PYDEGLRRGV FITNETGQPL IGKVWPGSTA FPDFTNPTAL AWWEDMVAEF 450
HDQVPFDGMW IDMNEPSNFI RGSEDGCPNN ELENPPYVPG VVGGTLQAAT 500
ICASSHQFLS THYNLHNLYG LTEAIASHRA LVKARGTRPF VISRSTFAGH 550
GRYAGHWTGD VWSSWEQLAS SVPEILQFNL LGVPLVGADV CGFLGNTSEE 600
LCVRWTQLGA FYPFMRNHNS LLSLPQEPYS FSEPAQQAMR KALTLRYALL 650
PHLYTLFHQA HVAGETVARP LFLEFPKDSS TWTVDHQLLW GEALLITPVL 700
QAGKAEVTGY FPLGTWYDLQ TVPIEALGSL PPPPAAPREP AIHSEGQWVT 750
LPAPLDTINV HLRAGYIIPL QGPGLTTTES RQQPMALAVA LTKGGEARGE 800
LFWDDGESLE VLERGAYTQV IFLARNNTIV NELVRVTSEG AGLQLQKVTV 850
LGVATAPQQV LSNGVPVSNF TYSPDTKVLD ICVSLLMGEQ FLVSWC     896
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
26-53 36-52 47-71 477-502 591-602 882-896

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-177 Asn-334 Asn-414 Asn-596 Asn-826 Asn-869

Methionine S-oxide / S-Oxyde de méthionine / S-Óxido de metionina (~50 %)
Met-66 Met-90 Met-116 Met-117

avapritinibum

avapritinib

(1*S*)-1-(4-fluorophenyl)-1-(2-{4-[6-(1-methyl-1*H*-pyrazol-4-yl)pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]piperazin-1-yl}pyrimidin-5-yl)ethan-1-amine

avapritinib

(1*S*)-1-(4-fluorophényl)-1-(2-{4-[6-(1-méthyl-1*H*-pyrazol-4-yl)pyrrolo[2,1-*f*][1,2,4]triazin-4-yl]pipérazin-1-yl}pyrimidin-5-yl)éthan-1-amine

avapritinib

(1*S*)-1-(4-fluorofenil)-1-(2-{4-[6-(1-metil-1*H*-pirazol-4-il)pirrolo[2,1-*f*][1,2,4]triazin-4-il]piperazin-1-il}pirimidin-5-il)etan-1-amina

$C_{26}H_{27}FN_{10}$



axicabtagenum ciloleucelum #

axicabtagene ciloleucel	human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the FMC63 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (FMC63-28Z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.
axicabtagène ciloleucel	Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélévé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de l'antigène chimérique FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (FMC63-28Z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
axicabtagén ciloleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (FMC63-28Z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.

beinaglutidum

beinaglutide	human glucagon-like peptide-1 (7-36)-peptide (GLP-1-(7-36))
béinaglutide	peptide 1 semblable au glucagon humain (7-36) (GLP-1-(7-36))
beinaglutida	péptido tipo 1 similar al glucagón humano (7-36) (GLP-1-(7-36))

$C_{149}H_{225}N_{39}O_{46}$

HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR 30

bemarituzumabum #

bemarituzumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, bacteria-expressed kinase, BEK, craniofacial dysostosis I, CFDI, Jackson-Weiss syndrome, JWS, CD332) isoform b (FGFR2b)], humanized monoclonal antibody; gamma1 heavy chain (1-444) [humanized VH (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), hinge (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (223-223'':226-226'')-bisdisulfide
bémarituzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, kinase exprimée dans des bactéries, BEK, dysostose craniofaciale I, CFDI, syndrome de Jackson-Weiss, JWS, CD332) isoforme b (FGFR2b)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-444) [VH humanisé (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), charnière (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfure avec la chaîne légère (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (223-223'':226-226'')-bisdisulfure
bemarituzumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de fibroblastos, receptor del factor de crecimiento de keratinocitos, KGFR, kinasa expresada en bacterias, BEK, disostosa craneofacial I, CFDI, síndrome de Jackson-Weiss, JWS, CD332) isoforma b (FGFR2b)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-444) [VH humanizado (*Homo sapiens* IGHV1-46*01 (80.60%) -(IGHD) -IGHJ4*01) [8.8.7] (1-114) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (211) (115-212), bisagra (213-227), CH2 (228-337), CH3 E12 (353), M14 (355) (338-442), CHS (443-444)) (115-444)], (217-214')-disulfuro con la cadena ligera (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-33*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (223-223'':226-226'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYIFT TYNVHWVRQA PGQGLEWIGS  50
IYPDNGDTSY NQNFKGRATI TADKSTSTAY MELSSLRSED TAVYYCARGD 100
FAYWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG CLVKDYFPEP 150
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSI GTQTYICNVN 200
HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP REPQVYTLPP 350
SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQGVS NDVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPS RFSGSGSGTD FTFTISSLQP EDIATYYCQQ HSTTPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 141-197 258-318 364-422
22"-96" 141"-197" 258"-318" 364"-422"

Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"

Inter-H-L (h 5-CL 126) 217-214' 217"-214'"

Inter-H-H (h 11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
294, 294"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados

bemcentinibum

bemcentinib — 1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-[(7*S*)-7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5*H*-benzo[7]annulen-2-yl]-1*H*-1,2,4-triazole-3,5-diamine

bemcentinib — 1-(6,7-dihydro-5*H*-benzo[6,7]cyclohepta[1,2-*c*]pyridazin-3-yl)-N^3-[(7*S*)-7-(pyrrolidin-1-yl)-6,7,8,9-tétrahydro-5*H*-benzo[7]annulén-2-yl]-1*H*-1,2,4-triazole-3,5-diamine

bemcentinib — 1-(6,7-dihidro-5*H*-benzo[6,7]ciclohepta[1,2-*c*]piridazin-3-il)-N^3-[(7*S*)-7-(pirrolidin-1-il)-6,7,8,9-tetrahidro-5*H*-benzo[7]anulen-2-il]-1*H*-1,2,4-triazol-3,5-diamina

$C_{30}H_{34}N_8$



berdazimerum natricum

berdazimer sodium — polysodium poly[{[3-(methylamino)propyl]silasesquioxane}-*co*-{[3-(1-methyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane}-*co*-silicate (1:3:6 x)], partially hydrolysed (Si : OH ~ 10 : 5)

berdazimère sodique

poly[{[3-(méthylamino)propyl]silasesquioxane}-*co*-{[3-(1-méthyl-2-nitroso-2-oxidohydrazin-1-yl)propyl]silasesquioxane}-*co*-silicate (1:3:6 x)] polysodique, partiellement hydrolysé (Si : OH ~ 10 : 5)

berdazímero de sodio

poli[{[3-(metilamino)propil]silasesquioxano}-*co*-{[3-(1-metil-2-nitroso-2-oxidohidrazin-1-il)propil]silasesquioxano}-*co*-silicato (1:3:6 x)] polisódico, parcialmente hidrolizado (Si : OH ~ 10 : 5)

$[(C_4\ H_9\ N_3\ Na\ O_{3.5}\ Si)_3\ (C_4\ H_{10}\ N\ O_{1.5}\ Si)\ (Si\ O_2)_6\ (H\ O_{0.5})_5]_{0.1n}$



w : *x* : *y* : *z* = 3 : 1 :6 : ~5

berlimatoxumabum #

berlimatoxumab

immunoglobulin G1-kappa, anti-[*Staphylococcus aureus* LukGH (LukAB) bi-component leukocidin], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (228-228''':231-231'')-bisdisulfide

berlimatoxumab

immunoglobuline G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidine à deux composants], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (228-228''':231-231'')-bisdisulfure

berlimatoxumab

inmunoglobulina G1-kappa, anti-[*Staphylococcus aureus* LukGH (Luk AB) leucocidina con dos componentes], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-448) [*Homo sapiens* VH (IGHV4-39*01 (94.90%) -(IGHD) -IGHJ6*04) [10.7.11] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (CH1 (120-217), bisagra(218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (228-228"':231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
ELQLQESGPG LVKPSETLSL TCTVSGGSIS SGSYYWDWIR QPPGKGLEWI  50
GNIYKSGSTY YNPSLKSRVT ISVDTSKNQF SLKLSSVTAA DTAVYYCARE 100
RGMHYMDVWG KGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQSIN SYLNWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ QFDPPFTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-97 146-202 263-323 369-427
22"-97" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 222-214' 222"-214'"
Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
299, 299"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados
G0F 42.5%, G1F 39.8%

berzosertibum

berzosertib

3-(3-{4-[(methylamino)methyl]phenyl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

berzosertib

3-(3-{4-[(méthylamino)méthyl]phényl}-1,2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

berzosertib

3-(3-{4-[(metilamino)metil]fenil}-1,2-oxazol-5-il)-5-[4-(propano-2-sulfonil)fenil]pirazin-2-amina

$C_{24}H_{25}N_5O_3S$



brexanolonum

brexanolone	3α-hydroxy-5α-pregnan-20-one
brexanolone	3α-hydroxy-5α-prègnan-20-one
brexanolona	3α-hidroxi-5α-pregnano-20-ona

$C_{21}H_{34}O_2$



camidanlumabum #

camidanlumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide
camidanlumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure
camidanlumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera

(1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYIINWVRQA PGQGLEWMGR  50
IIPILGVENY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARKD 100
WFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK      445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYG  50
ASSRATGIPD RFSGSGSGTD FTLTISRLEP EDFAVYYCQQ YGSSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 142-198 259-319 365-423
22"-96" 142"-198" 259"-319" 365"-423"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 218-214' 218"-214'"
Inter-H-H (h 11, h 14) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

camidanlumabum tesirinum #
camidanlumab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], *Homo sapiens* monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX;
gamma1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), hinge (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide; conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG (n=8)

For the *tesirine* part, please refer to the prop.INN List 113, published in *the WHO Drug Information, Vol.29, No.2, 2015.*

camidanlumab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticorps monoclonal conjugué au dimère de pyrrolobenzodiazépine (PDB) SCX;

chaîne lourde gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), charnière (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224''':227-227''')-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8).
Pour la partie *tésirine*, veuillez vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information, Vol.29, No.2, 2015.*

camidanlumab tesirina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], *Homo sapiens* anticuerpo monoclonal conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX;
cadena pesada gamma1 (1-445) [*Homo sapiens* VH (IGHV1-69*02 (94.90%) -(IGHD) -IGHJ4*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (212) (116-213), bisagra (214-228), CH2 (229-338), CH3 E12 (354), M14 (356) (339-443), CHS (444-445)) (116-445)], (218-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224''':227-227''')-bisdisulfuro; conjugado, en una media de 2 cisteínas, al dímero de pirrolobenzodiazepina (PBD) SCX, mediante un espaciador escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida que comprende un espaciador PEG (n=8)
Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information, Vol.29, No.2, 2015.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS RYIINWVRQA PGQGLEWMGR  50
IIPILGVENY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARKD 100
WFDYWGQGTL VTVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KRVEPKSCDK THTCPPCPAP ELLGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLP 350
PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK       445
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYG  50
ASSRATGIPD RFSGSGSGTD FTLTISRLEP EDFAVYYCQQ YGSSPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 142-198 259-319 365-423
22"-96" 142"-198" 259"-319" 365"-423"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) * 218-214' 218"-214'"
Inter-H-H (h 11, h 14) * 224-224" 227-227"
*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan uno o dos puentes disulfuro inter-catenarios, una media de 2 cisteinil están conjugados con sendos enlaces tioéter, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

canerpaturevum #

canerpaturev	Replication-competent, spontaneously occurring mutant of Herpes Simplex Virus type 1 (HSV-1) with a number of deletions and insertions in the genome, resulting in the lack of functional expression of UL43, UL49.5, UL55 and UL56.
canerpaturev	mutant spontané de Virus Herpes Simplex type 1 (HSV-1) capable de se répliquer, avec un nombre de délétions et d'insertions dans le génome, résultant en l'absence de l'expression fonctionnelle des gènes UL43, UL49.5, UL55et UL56.
canerpaturev	Virus Herpes Simplex tipo 1 (HSV-1) competente de replicación, mutado espontáneamente, con un número de deleciones e inserciones en el genoma que dan como resultado la ausencia de expresión functional de los genes UL43, UL49.5, UL55 y UL56.

capivasertibum

capivasertib	4-amino-*N*-[(1*S*)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-carboxamide
capivasertib	4-amino-*N*-[(1*S*)-1-(4-chlorophényl)-3-hydroxypropyl]-1-(1*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)pipéridine-4-carboxamide
capivasertib	4-amino-*N*-[(1*S*)-1-(4-clorofenil)-3-hidroxipropil]-1-(1*H*-pirrolo[2,3-*d*]pirimidin-4-il)piperidina-4-carboxamida

$C_{21}H_{25}ClN_6O_2$



cobomarsenum

cobomarsen	*all-P-ambo*-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-methylene-*P*-thioadenylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-5-methyl-2'-*O*,4'-*C*-methylene-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-methyleneadenosine

cobomarsen

tout-P-ambo-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiouridylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiouridylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-*O*,4'-*C*-méthylène-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-méthylène-*P*-thioadénylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiouridylyl-(3'→5')-5-méthyl-2'-*O*,4'-*C*-méthylène-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-méthylèneadénosine

cobomarsén

todo-P-ambo-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*,4'-*C*-metileno-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-metileno-*P*-tioadenilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-5-metil-2'-*O*,4'-*C*-metileno-*P*-tiouridilil-(3'→5')-2'-*O*,4'-*C*-metileneadenosina

$C_{148}H_{177}N_{52}O_{77}P_{13}S_{13}$

(3'-5')(*P*-thio)(m^{5}C-dA-m^{5}C-dG-dA-m^{5}U-m^{5}U-dA-G-dC-A-m^{5}U-m^{5}U-A)



dX : 2'-deoxy-X / dX : 2'-désoxy-X / dX: 2'-desoxi-X

cofetuzumabum #
cofetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide

cofétuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228'':231-231'')-bisdisulfure
cofetuzumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa del cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLEWIGV  50
ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSRLRSED TAVYYCARGN 100
SYFYALDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESVD SYGKSFMHWY QQKPGQAPRL  50
LIYRASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSNEDPW 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22''-96'' 146''-202'' 263''-323'' 369''-427''

Intra-L (C23-C104) 23'-92' 138'-198'
23'''-92''' 138'''-198'''

Inter-H-L (h 5-CL 126) 222-218' 222''-218'''

Inter-H-H (h 11, h 14) 228-228'' 231-231''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299''

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

cofetuzumabum pelidotinum #

cofetuzumab pelidotin	immunoglobulin G1-kappa, anti-[*Homo sapiens* PTK7 (protein tyrosine kinase 7, colon carcinoma kinase 4, CCK4) extracellular domain], humanized monoclonal antibody, conjugated to auristatin-0101; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), hinge (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to auristatin-0101 (Aur0101), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
cofétuzumab pélidotine	immunoglobuline G1-kappa, anti-[*Homo sapiens* PTK7 (protéine tyrosine kinase 7, kinase du cancer du côlon, CCK4) domaine extracellulaire], anticorps monoclonal humanisé, conjugué à l'auristatine-0101; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), charnière (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, à l'auristatine-0101 (Aur0101), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)
cofetuzumab pelidotina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* PTK7 (proteína tirosina kinasa 7, kinasa de cáncer de colon, CCK4) dominio extracelular], anticuerpo monoclonal humanizado, conjugado con la auristatina-0101; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-3*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (216) (120-217), bisagra (218-232), CH2 (233-342), CH3 D12 (358), L14 (360) (343-447), CHS K>del (448)) (120-448)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 A45.1 (157), V101 (195) (112'-218')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en una media de 3 a 4 restos cisteinil, con la auristatina-0101 (Aur0101), mediante un conector escindible de tipo maleimidocaproil-valil-citrulinil-*p*-aminobenziloxicarbonil (mc-val-cit-PABC)

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGPE VKKPGASVKV SCKASGYTFT DYAVHWVRQA PGKRLEWIGV  50
ISTYNDYTYN NQDFKGRVTM TRDTSASTAY MELSRLRSED TAVYYCARGN 100
SYFYALDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASESVD SYGKSFMHWY QQKPGQAPRL  50
LIYRASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCQQSNEDPW 100
TFGGGTKLEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L (h 5-CL 126) * 222-218' 222"-218'"
Inter-H-H (h 11, h 14) * 228-228" 231-231"

Modified residues / résidus modifiés / restos modificados



N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

crenigacestatum

crenigacestat — 4,4,4-trifluoro-*N*-[(2*S*)-1-{[(7*S*)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5*H*-pyrido[3,2-*a*][3]benzoxazepin-7-yl]amino}-1-oxopropan-2-yl]butanamide

crénigacestat — 4,4,4-trifluoro-*N*-[(2*S*)-1-{[(7*S*)-5-(2-hydroxyéthyl)-6-oxo-6,7-dihydro-5*H*-pyrido[3,2-*a*][3]benzoxazépin-7-yl]amino}-1-oxopropan-2-yl]butanamide

crenigacestat — 4,4,4-trifluoro-*N*-[(2*S*)-1-{[(7*S*)-5-(2-hidroxietil)-6-oxo-6,7-dihidro-5*H*-pirido[3,2-*a*][3]benzoxazepin-7-il]amino}-1-oxopropan-2-il]butanamida

$C_{22}H_{23}F_3N_4O_4$



danvatirsenum

danvatirsen

all-P-ambo-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thioguanylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-5-methylcytidine

danvatirsen

tout-P-ambo-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thioadénylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thioguanylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-5-méthylcytidine

danvatirsén

todo-P-ambo-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-5-metil-*P*-tiouridilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tioadenilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tioguanilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-5-metilcitidina

$C_{172}H_{217}N_{56}O_{88}P_{15}S_{15}$



darvadstrocelum

darvadstrocel	Human culture expanded allogeneic adipose stromal progenitor cells (eASC) for cell-based therapy. Cells are derived from isolated adipose tissue of healthy living donors. eASC express cell surface markers CD29, CD73, CD90 and CD105 and are capable to express factors such as vascular endothelial growth factor (VEGF), transforming growth factor-beta 1 (TGF-β1), interleukin-6 (IL-6), matrix metalloproteinase inhibitor-1 (TIMP-1), and interferon-gamma (IFN-γ) inducible indoleamine 2,3-dioxygenase (IDO).
darvadstrocel	Cellules progénitrices humainesallogéniques du stroma adipeux (eASC), en culture d'expansion, pour thérapie à base de cellules. Les cellules sont dérivées d'un tissu adipeux isolé à partir de donneurs vivants sains. Les eASC expriment les marqueurs de surface CD29, CD73, CD90 et CD105 et sont capables d'exprimer les facteurs comme le facteur de croissance de l'endothélium vasculaire (VEGF), le facteur de croissance transformant beta 1 (TGF-β1), l'interleukine 6 (IL-6), l'inhibiteur tissulaire des métalloprotéases 1 (TIMP-1) et l'indoléamine 2,3-dioxygénase (IDO) induite par l'interféron gamma (IFN-γ).
darvadstrocel	Células progenitoras del estroma adiposo alogénicas, humanas, expandidas en cultivo (eASC) para terapia celular. Las células se derivan a partir tejido adiposo aislado de donantes sanos vivos. Las eASC expresan los marcadores de superficie CD29, CD73, CD90 y CD105, y pueden expresar factores como el factor de crecimiento del endotelio vascular (VEGF), factor transformador del crecimiento beta 1 (TGF- β1), interleukina 6 (IL-6), inhibidor de metaloproteinasa de la matriz 1 (TIMP-1), e indoleamina 2,3- dioxigenasa (IDO) inducible por interferón gamma (IFN-γ) .

davamotecanum pegadexamerum

davamotecan pegadexamer	α-acetyl-ω-{[(2*RS*)-2-hydroxypropyl]amino}poly[({bis[(4*S*)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] *S,S'*-(6^{I},6^{IV}-dideoxycyclomaltoheptaose-6^{I},6^{IV}-diyl)bis(L-cysteinylglycinate)}-$N^{2.1}$,N$^{2.1'}$-diyl)(1-oxopropane-1,3-diyl)poly(oxyethylene)oxy(3-oxopropane-1,3-diyl)]
davamotécan pégadexamère	α-acétyl-ω-{[(2*RS*)-2-hydroxypropyl]amino}poly[({bis[(4*S*)-4-éthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl] *S,S'*-(6^{I},6^{IV}-didésoxycyclomaltoheptaose-6^{I},6^{IV}-diyl)bis(L-cystéinylglycinate)}-$N^{2.1}$,N$^{2.1'}$-diyl)(1-oxopropane-1,3-diyl)poly(oxyéthylène)oxy(3-oxopropane-1,3-diyl)]
davamotecán pegadexámero	α-acetil-ω-{[(2*RS*)-2-hidroxipropil]amino}poli[({bis[(4*S*)-4-etil-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-b]quinolin-4-il] *S,S'*-(6^{I},6^{IV}-didesoxiciclomaltoheptaosa-6^{I},6^{IV}-diil)bis(L-cisteinilglicinato)}-$N^{2.1}$,N$^{2.1'}$-diil)(1-oxopropano-1,3-diil)poli(oxietileno)oxi(3-oxopropano-1,3-diil)]

C_2H_3O-($C_{252}H_{428}N_8O_{125}S_2$)$_n$-$C_3H_8NO$



delgocitinibum

delgocitinib	3-[(3*S*,4*R*)-3-methyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
delgocitinib	3-[(3*S*,4*R*)-3-méthyl-6-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
delgocitinib	3-[(3*S*,4*R*)-3-metil-6-(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)-1,6-diazaspiro[3.4]octan-1-il]-3-oxopropanenitrilo

$C_{16}H_{18}N_6O$



demplatinum pegraglumerum

demplatin pegraglumer	{[α-{3-[α-*N*-hydropoly(L-glutamyl-κ*O*^{5})$_m$-ω-amino]propyl}-ω-methoxypoly(oxyethane-1,2-diyl)$_n$]polyato}poly[*cis*-(*SP*-4)-aquadiammineplatinum(II)/*cis*-(*SP*-4)-diammineplatinum(II) (x:y)], with m ~ 40, n ~ 268, x ~ 8, (m+x)/2 = 24
demplatine pégraglumère	{[α-{3-[α-*N*-hydropoly(L-glutamyl-κ*O*^{5})$_m$-ω-amino]propyl}-ω-méthoxypoly(oxyéthane-1,2-diyl)$_n$]polyato}poly[*cis*-(*SP*-4)-aquadiammineplatine(II)/*cis*-(*SP*-4)-diammineplatine(II) (x:y)], avec m ~ 40, n ~ 268, x ~ 8, (m+x)/2 = 24

demplatino pegraglúmero

{[α-{3-[α-*N*-hidropoli(L-glutamil-κO^5)$_m$-ω-amino]propil}-ω-metoxipoli(oxietano-1,2-diil)$_n$]poliato}poli[*cis*-(*SP*-4)-aquadiammineplatino(II)/*cis*-(*SP*-4)-diammineplatino(II)] (x:y)], con m ~ 40, n ~ 268, x ~ 8, (m+x)/2 = 24

$C_4H_{11}NO(C_5H_6NO_3)_m(CH_2CH_2O)_n(H_6N_2Pt)_{(m+x)/2}(H2O)_x$



m ~ 40, *n* ~ 268, *x* ~ 8, (*m* + *x*)/2 = 24

desidustatum

desidustat

N-[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl]glycine

désidustat

N-[1-(cyclopropylméthoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoléine-3-carbonyl]glycine

desidustat

N-[1-(ciclopropilmetoxi)-4-hidroxi-2-oxo-1,2-dihidroquinoleína-3-carbonil]glicina

$C_{16}H_{16}N_2O_6$



desmetramadolum

desmetramadol

rac-3-{(1*R*,2*R*)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl}phenol

desmétramadol

rac-3-{(1*R*,2*R*)-2-[(diméthylamino)méthyl]-1-hydroxycyclohexyl}phénol

desmetramadol

rac-3-{(1*R*,2*R*)-2-[(dimetilamino)metil]-1-hidroxiciclohexil}fenol

$C_{15}H_{23}NO_2$



and enantiomer
et énantiomère
y enantiómero

efepoetinum alfa #

efepoetin alfa

human erythropoietin (epoetin alfa) fused to a hybrid human immunoglobulin (Ig), consisting of the Fc fragment of the IgG4 fused to the hinge and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

[human erythropoietin (EPO) (1-166)]-[immunoglobulin heavy chain delta (IGHD) isoform 2 constant region (133-170)-peptide (C-terminal hinge region and N-terminal CH2 domain) (167-204)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (205-411)]-fusion protein, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

éfépoétine alfa

érythropoïétine humaine (époétine alfa) fusionée à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotoype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

[érythropoïétine humaine (EPO) (1-166)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (167-204)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (205-411)]- protéine de fusion, produite par des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

efepoetina alfa

eritropoyetina humana (epoetina alfa) fusionada con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionada con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producia por las células ováricas de hamster chino (CHO), glicoforma alfa;

[eritropoyetina humana (EPO) (1-166)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (167-204)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (205-411)]- proteína de fusión, producida por las células ováricas de hamster chinos (CHO), glicoforma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT VPDTKVNFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQPWEP LQLHVDKAVS 100
GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR 150
GKLKLYTGEA CRTGDRRNTG RGGEEKKKEK EKEEQEERET KTPECPSHTQ 200
PLGVFLFPPK PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN 250
AKTKPREEQF NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI 300
SKAKGQPREP QVYTLPPSQE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ 350
PENNYKTTPP VLDSDGSFFL YSRLTVDKSR WQEGNVFSCS VMHEALHNHY 400
TQKSLSLSLG K                                          411
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain disulfide bridges: 7-161 29-33 225-285 331-389
7'-161' 29'-33' 225'-285' 331'-389'

Inter-chain disulfide bridges: 195-195'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-24 Asn-38 Asn-83 Asn-261

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)

Ser-126

efizonerimodum alfa #

efizonerimod alfa

modified human immunoglobulin G4 Fc fragment fused to tumor necrosis factor receptor-associated factor TRAF2 (human C-C domain fragment) and to the CD252 antigen (human extracellular domain fragment), hexamer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

modified human immunoglobulin G4 Fc fragment (1-229) [*Homo sapiens* IGHG4*01 del-CH1, [10-proline (S>P)]hinge] fusion protein with human TNF receptor-associated factor2 (TRAF2)-(310-349)-peptide (230-269) fusion protein with des-(1-50)-human tumor necrosis factor ligand superfamily member4 (TNFSF4, also known as CD252 or OX40L) (270-402), produced in Chinese hamster ovary (CHO) cells, non-covalent trimer of (8-8',11-11')-bisdisulfide dimers, glycoform alfa

éfizonérimod alfa

fragment Fc modifié de l'immunoglobuline G4 humaine, fusionné au facteur associé au récepteur du facteur de nécrose tumorale TRAF2 (fragment du domaine C-C humain) et à l'antigène CD252 (fragment du domaine extracellulaire humain), héxamère, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

fragment Fc modifié de l'immunoglobuline G4 humaine (1-229)[*Homo sapiens* IGHG4*01 del-CH1, [10-proline (S>P)]charnière] protéine de fusion avec le facteur 2 associé au récepteur du TNF humain (TRAF2)-(310-349)-peptide (230-269) protéine de fusion avec le dès-(1-50)-membre 4 de la superfamille des ligands du facteur de nécrose tumorale humain (TNFSF4, CD252, OX40L) (270-402), produit dans des cellules ovariennes de hamster chinois (CHO), trimère non-covalent de dimères (8-8',11-11')-bisdisulfure, glycoforme alfa

efizonerimod alfa

fragmento Fc modificado de la inmunoglobulina G4 humana, fusionada con el factor asociado al receptor del factor de necrosis tumoral TRAF2 (fragmento del dominio C-C humano) y al antígeno CD252 (fragmento del dominio extracelular humano), hexámero, producido en las células ováricas de hámsters chinos (CHO), glicoforma alfa;

fragmento Fc modificado de la inmunoglobulina G4 humana (1-229)[*Homo sapiens* IGHG4*01 del-CH1, [10-prolina (S>P)]bisagra] proteína de fusión con el factor 2 asociado al receptor del TNF humano (TRAF2)-(310-349)-péptido (230-269) proteína de fusión con el des-(1-50)- miembro 4 de la superfamilia de los ligandos del factor de necrosis tumoral humano (TNFSF4, CD252, OX40L) (270-402), producido en las células ováricas de hámster chino (CHO), trímero no-covalente de dímeros (8-8',11-11')-bisdisulfuro, glicoforma alfa



Monomer sequence / Séquence du monomère / Secuencia del monómero

```
ESKYGPPCPP CPAPEFLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSQ 50
EDPEVQFNWY VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE 100
YKCKVSNKGL PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL 150
VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ 200
EGNVFSCSVM HEALHNHYTQ KSLSLSLGKD QDKIEALSSK VQQLERSIGL 250
KDLAMADLEQ KVLEMEASTQ VSHRYPRIQS IKVQFTEYKK EKGFILTSQK 300
EDEIMKVQNN SVIINCDGFY LISLKGYFSQ EVNISLHYQK DEEPLFQLKK 350
VRSVNSLMVA SLTYKDKVYL NVTTDNTSLD DFHVNGGELI LIHQNPGEFC 400
VL                                                    402
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
8-8' 11-11' 43-103 149-207 316-400

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-79 Asn-309 Asn-333 Asn-371 Asn-376

eflenograstimum alfa #

eflenograstim alfa	human granulocyte-colony stimulating factor (G-CSF) fused to a hybrid human immunoglobulin consisting of the Fc fragment of the IgG4 fused to the hinge region and amino-terminus of the IgD heavy chain isotype 2, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; [human granulocyte-colony stimulating factor (G-CSF) short isoform (1-174)]-[immunoglobulin heavy chain delta (IGHD) constant region isoform 2 (133-170)-peptide (C-terminal hinge and N-terminal CH2 domains) (175-212)]-[immunoglobulin heavy chain gamma 4 (IGHG4) constant region (121-327)-peptide (CH2 and CH3 domains) (213-419)]-fusion protein, (203-203')-disulfide dimer, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
éflénograstim alfa	facteur stimulant les colonies de granulocytes humain (G-CSF) fusionné à une immunoglobuline (Ig) humaine hybride, consistant en un fragment Fc de l'IgG4 fusionné à la région charnière et à la chaîne lourde isotoype 2 de l'IgD sur la partie N-terminale, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa; [facteur stimulant les colonies de granulocytes humain (G-CSF) isoforme courte (1-174)]-[région constante de la chaîne lourde delta de l'immunoglobuline (IGHD) isoforme 2 (133-170)-peptide (région charnière C-terminale et domaine CH2 N-terminal) (175-212)]-[région constante de la chaîne lourde de l'immunoglobuline gamma 4 (IGHG4) (121-327)-peptide (domaines CH2 et CH3) (213-419)]-protéine de fusion, (203-203')-disulfide dimère, produite par des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa
eflenograstim alfa	factor estimulante de las colonias de granulocitos humanos (G-CSF) fusionado con una inmunoglobulina (Ig) humana híbrida, consistente en un fragmento Fc de la IgG4 fusionado con la región bisagra y con la cadena pesada isótopo 2 de la IgD sobre la parte N-terminal, producido por las células ováricas de hamster chino (CHO), glicoforma alfa; [factor estimulante de las colonias de granulocitos humanos (G-CSF) isoforma corta (1-174)]-[región constante de la cadena pesada delta de la inmunoglobulina (IGHD) isoforma 2 (133-170)-péptido (región bisagra C-terminal y dominio CH2 N-terminal) (175-212)]-[región constante de la cadena pesada de la inmunoglobulina gamma 4 (IGHG4) (121-327)-péptido (dominios CH2 y CH3) (213-419)]-proteína de fusión, (203-203')-disulfuro dímero, producido por las células ováricas de hamster chino (CHO), glicoforma alfa

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
TPLGPASSLP QSFLLKCLEQ VRKIQGDGAA LQEKLCATYK LCHPEELVLL 50
GHSLGIPWAP LSSCPSQALQ LAGCLSQLHS GLFLYQGLLQ ALEGISPELG 100
PTLDTLQLDV ADFATTIWQQ MEELGMAPAL QPTQGAMPAF ASAFQRRAGG 150
VLVASHLQSF LEVSYRVLRH LAQPRNTGRG GEEKKKEKEK EEQEERETKT 200
PECPSHTQPL GVFLFPPKPK DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY 250
VDGVEVHNAK TKPREEQFNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL 300
PSSIEKTISK AKGQPREPQV YTLPPSQEEM TKNQVSLTCL VKGFYPSDIA 350
VEWESNGQPE NNYKTTPPVL DSDGSFFLYS RLTVDKSRWQ EGNVFSCSVM 400
HEALHNHYTQ KSLSLSLGK                                   419
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain disulfide bridges: 36-42 64-74 233-293 339-397
36'-42' 64'-74' 233'-293' 339'-397'
Inter-chain disulfide bridges: 203-203'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-269

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Thr-133

elenbecestatum

elenbecestat — *N*-{3-[(4a*S*,5*R*,7a*S*)-2-amino-5-methyl-4a,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7a(7*H*)-yl]-4-fluorophenyl}-5-(difluoromethyl)pyrazine-2-carboxamide

élenbécestat — *N*-{3-[(4a*S*,5*R*,7a*S*)-2-amino-5-méthyl-4a,5-dihydro-4*H*-furo[3,4-*d*][1,3]thiazin-7a(7*H*)-yl]-4-fluorophényl}-5-(difluorométhyl)pyrazine-2-carboxamide

elenbecestat — *N*-{3-[(4a*S*,5*R*,7a*S*)-2-amino-5-metil-4a,5-dihidro-4*H*-furo[3,4-*d*][1,3]tiazin-7a(7*H*)-il]-4-fluorofenil}-5-(difluorometil)pirazina-2-carboxamida

$C_{19}H_{18}F_3N_5O_2S$



elsulfavirinum

elsulfavirine — *N*-(4-{2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetamido}-3-chlorobenzenesulfonyl)propanamide

elsulfavirine — *N*-(4-{2-[4-bromo-3-(3-chloro-5-cyanophénoxy)-2-fluorophényl]acétamido}-3-chlorobenzènesulfonyl)propanamide

elsulfavirina — *N*-(4-{2-[4-bromo-3-(3-cloro-5-cianofenoxi)-2-fluorofenil]acetamido}-3-clorobencenosulfonil)propanamida

$C_{24}H_{17}BrCl_2FN_3O_5S$



emiplacelum

emiplacel	human culture expanded allogenic adherent mesenchymal-like stromal cells for cell-based therapy. Cells are derived of maternal origin from isolated placentae of healthy donors following a cesarean section. Cells express cell surface markers CD29, CD73, and CD105 and exhibit immunomodulatory, pro-angiogenic and muscle regeneration effects.
émiplacel	cellules mésenchymales adhérentes humaines allogéniques semblables au stroma, en culture d'expansion, pour thérapie cellulaire. Les cellules d'origine maternelle sont obtenues à partir du placenta de donneuses saines et vivantes suivant une césarienne. Les cellules expriment les marqueurs de surface CD29, CD73, and CD105 et montrent des propriétés immunomodulatrices et des effets pro-angiogéniques.
emiplacel	células adherentes mesenquimales similares al estroma alogénicas, humanas, expandidas en cultivo para terapia celular. Las células de origén maternal se derivan a partir de la placenta de donantes sanos vivos tras una sección por cesárea. Las células expresan los marcadores de superficie CD29, CD73 y D105, y muestran efectos inmunomoduladores y angiogénicos

enarodustatum

enarodustat	*N*-[7-hydroxy-5-(2-phenylethyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine
énarodustat	*N*-[7-hydroxy-5-(2-phényléthyl)[1,2,4]triazolo[1,5-*a*]pyridine-8-carbonyl]glycine
enarodustat	*N*-[7-hidroxi-5-(2-feniletil)[1,2,4]triazolo[1,5-*a*]piridina-8-carbonil]glicina

$C_{17}H_{16}N_4O_4$



estetrolum

estetrol — estra-1,3,5(10)-triene-3,15α,16α,17β-tetrol

estétrol — estra-1,3,5(10)-triène-3,15α,16α,17β-tétrol

estetrol — estra-1,3,5(10)-trieno-3,15α,16α,17β-tetrol

$C_{18}H_{24}N_4$



exebacasum #

exebacase — *Streptococcus suis* bacteriophage-derived lysin**,** produced in *Escherichia coli*;

des-Met[1]-phage lysin (endolysin, lysozyme, murein hydrolase, EC 3.2.1.17) of *Streptococcus suis phage* φ891591 (PlySs2), produced in *Escherichia coli*

exébacase — lysine dérivée du bactériophage *Streptococcus suis***,** produite par *Escherichia coli;*

lysine du dès-Mét[1]-phage *Streptococcus suis* φ891591 (PlySs2) (endolysine, lysozyme, muréine hydrolase, EC 3.2.1.17), produite par *Escherichia coli*

exebacasa — lisina derivada del bacteriófago *Streptococcus suis***,** producido por *Escherichia coli;*

lisina del des-Met[1]-fago *Streptococcus suis* φ891591 (PlySs2) (endolisina, lisozima, mureína hidrolasa, EC 3.2.1.17), producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```
TTVNEALNNV RAQVGSSGVSV GNGECYALAS WYERMISPDA TVGLGAGVGW 50
VSGAIGDTIS AKNIGSSYNW QANGWTVSTS GPFKAGQIVT LGATPGNPYG 100
HVVIVEAVDG DRLTILEQNY GGKRYPVRNY YSAASYRQQV VHYITPPGTV 150
AQSAPNLAGS RSYRETGTMT VTVDALNVRR APNTSGEIVA VYKRGESFDY 200
DTVIIDVNGY VWVSYIGGSG KRNYVATGAT KDGKRFGNAW GTFK       244
```

fenebrutinibum

fenebrutinib — (6[2]*S*)-2[3]-(hydroxymethyl)-1[7],1[7],3[1],6[2]-tetramethyl-1[3],1[4],1[7],1[8]-tetrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-*a*]pyrazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripyridina-7(3)-oxetanaheptaphane-1[1](1[6]*H*),3[6](3[1]*H*)-dione

fénébrutinib — (6[2]*S*)-2[3]-(hydroxyméthyl)-1[7],1[7],3[1],6[2]-tétraméthyl-1[3],1[4],1[7],1[8]-tétrahydro-4-aza-1(2)-cyclopenta[4,5]pyrrolo[1,2-*a*]pyrazina-6(1,4)-pipérazina-2(2,4),3(3,5),5(2,5)-tripyridina-7(3)-oxétanaheptaphane-1[1](1[6]*H*),3[6](3[1]*H*)-dione

fenebrutinib

(6^{2}*S*)-2^{3}-(hidroximetil)-1^{7},1^{7},3^{1},6^{2}-tetrametil-1^{3},1^{4},1^{7},1^{8}-tetrahidro-4-aza-1(2)-ciclopenta[4,5]pirrolo[1,2-*a*]pirazina-6(1,4)-piperazina-2(2,4),3(3,5),5(2,5)-tripiridina-7(3)-oxetanaheptafano-1^{1}(1^{6}*H*),3^{6}(3^{1}*H*)-diona

$C_{37}H_{44}N_8O_4$



firibastatum

firibastat

4,4'-disulfanediylbis[(3*S*)-3-aminobutane-1-sulfonic] acid

firibastat

acide 4,4'-disulfanediylbis[(3*S*)-3-aminobutane-1-sulfonique]

firibastat

ácido 4,4'-disulfanodiilbis[(3*S*)-3-aminobutano-1-sulfónico]

$C_8H_{20}N_2O_6S_4$



foligluraxum

foliglurax

N-{6-[3-(morpholin-4-yl)propyl]-2-(thieno[3,2-*c*]pyridin-6-yl)-4*H*-1-benzopyran-4-ylidene}hydroxylamine

foliglurax

N-{6-[3-(morpholin-4-yl)propyl]-2-(thiéno[3,2-*c*]pyridin-6-yl)-4*H*-1-benzopyran-4-ylidène}hydroxylamine

foliglurax

N-{6-[3-(morfolin-4-il)propil]-2-(tieno[3,2-*c*]piridin-6-il)-4*H*-1-benzopiran-4-ilideno}hidroxilamina

$C_{23}H_{23}N_3O_3S$



fulacimstatum

fulacimstat — 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluoromethyl)-2,3-dihydro-1*H*-inden-1-yl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

fulacimstat — acide 1-(3-méthyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1*R*)-4-(trifluorométhyl)-2,3-dihydro-1*H*-indén-1-yl]-1,2,3,4-tétrahydropyrimidine-5-carboxylique

fulacimstat — ácido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1*R*)-4-(trifluorometil)-2,3-dihidro-1*H*-inden-1-il]-1,2,3,4-tetrahidropirimidina-5-carboxílico

$C_{23}H_{16}F_3N_3O_6$



garvagliptinum

garvagliptin — (2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[5-(methanesulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptine — (2*R*,3*S*,5*R*)-2-(2,5-difluorophényl)-5-[5-(méthanesulfonyl)-3,4,5,6-tétrahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl]oxan-3-amine

garvagliptina — (2*R*,3*S*,5*R*)-2-(2,5-difluorofenil)-5-[5-(metanosulfonil)-3,4,5,6-tetrahidropirrolo[3,4-*c*]pirrol-2(1*H*)-il]oxan-3-amina

$C_{18}H_{23}F_2N_3O_3S$



gimsilumabum #

gimsilumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dimer (230-230'':233-233'')-bisdisulfide

gimsilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dimère (230-230'':233-233'')-bisdisulfure

gimsilumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CSF2 (factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-74*03 (84.70%) -(IGHD) -IGHJ4*01, L123>P (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 G1m17,1 (CH1 K120 (218) (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 D12 (360), L14 (362), M107>V (432) (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (89.50%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (108'-214')]; dímero (230-230'':233-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RHWMHWLRQV PGKGPVWVSR  50
INGAGTSITY ADSVRGRFTI SRDNANNTLF LQMNSLRADD TALYFCARAN 100
SVWFRGLFDY WGQGTPVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VVHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPVT LSVSPGERVT LSCRASQSVS TNLAWYQQKL GQGPRLLIYG  50
ASTRATDIPA RFSGSGSETE FTLTISSLQS EDFAVYYCQQ YDKWPDTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 224-214' 224"-214'"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H VH N84
76, 76"
H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ianalumabum #	
ianalumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03,G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide
ianalumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF13C (membre 13C de la super famille du récepteur du facteur de nécrose tumorale (TNFR), BAFFR, BAFF-R, BR3, récepteur du facteur d'activation des lymphocytes B], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfure avec la chaîne légère (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimère (233-233'':236-236'')-bisdisulfure
ianalumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TNFRSF13C (miembro 13C de la super familia del receptor del factor de necrosis tumoral (TNFR), BAFFR, BAFF-R, BR3, receptor del factor de activación de los linfocitos B], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfuro con la cadena ligera (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*01 (86.80%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dímero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPG LVKPSQTLSL TCAISGDSVS SNSAAWGWIR QSPGRGLEWL  50
GRIYYRSKWY NSYAVSVKSR ITINPDTSKN QFSLQLNSVT PEDTAVYYCA 100
RYQWVPKIGV FDSWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPAT LSLSPGERAT LSCRASQFIL PEYLSWYQQK PGQAPRLLIY  50
GSSSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QFYSSPLTFG 100
QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-99 151-207 268-328 374-432
22"-99" 151"-207" 268"-328" 374"-432"
Intra-L (C23-C104) 23'-89' 135'-195'
23'"-89'" 135'"-195'"
Inter-H-L (h 5-CL 126) 227-215' 227"-215'"
Inter-H-H (h 11, h 14) 233-233" 236-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 304"
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos afucosilados
N-terminal glutamine cyclization
H VH Q1: 1, 1"
C-terminal lysine clipping
H CHS K2: 454, 454"

iberdomidum
iberdomide — (3*S*)-3-[4-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl]piperidine-2,6-dione

iberdomide — (3*S*)-3-[4-({4-[(morpholin-4-yl)méthyl]phényl}méthoxy)-1-oxo-1,3-dihydro-2*H*-isoindol-2-yl]pipéridine-2,6-dione

iberdomida — (3*S*)-3-[4-({4-[(morfolin-4-il)metil]fenil}metoxi)-1-oxo-1,3-dihidro-2*H*-isoindol-2-il]piperidina-2,6-diona

$C_{25}H_{27}N_3O_5$



imlifidasum #
imlifidase — human immunoglobulin G-degrading cysteine protease from *Streptococcus pyogenes* (IdeS, residues 30-339), produced in *Escherichia coli*; L-methionyl-immunoglobulin G-degrading protease (*Streptococcus pyogenes*) (IdeS) pro-protein (30-339)-peptide, produced by *Escherichia coli*

imlifidase

cystéine protéase de *Streptococcus pyogenes* dégradant l'immunoglobuline G humaine (IdeS, résidus 30-339), produite par *Escherichia coli*;
L-méthionyl-protéase dégradant l'immunoglobuline G (*Streptococcus pyogenes*) (IdeS) pro-protéine (30-339)-peptide, produite par *Escherichia coli*

imlifidasa

cisteína proteasa de *Streptococcus pyogenes* que degrada a la inmunoglobulina G humana (IdeS, residuos 30-339), producida por *Escherichia coli*;
L-metionil-proteasa que degrada la inmunoglobulina G (*Streptococcus pyogenes*) (IdeS) pro-proteína (30-339)-péptido, producido por *Escherichia coli*

Sequence / Séquence / Secuencia

```
MDSFSANQEI RYSEVTPYHV TSVWTKGVTP PANFTQGEDV FHAPYVANQG 50
WYDITKTFNG KDDLLCGAAT AGNMLHWWFD QNKDQIKRYL EEHPEKQKIN 100
FNGEQMFDVK EAIDTKNHQL DSKLFEYFKE KAFPYLSTKH LGVFPDHVID 150
MFINGYRLSL TNHGPTPVKE GSKDPRGGIF DAVFTRGDQS KLLTSRHDFK 200
EKNLKEISDL IKKELTEGKA LGLSHTYANV RINHVINLWG ADFDSNGNLK 250
AIYVTDSDSN ASIGMKKYFV GVNSAGKVAI SAKEIKEDNI GAQVLGLFTL 300
STGQDSWNQT N                                           311
```

istiratumabum #

istiratumab

immunoglobulin G1-kappa anti-[*Homo sapiens* IGF1R (insulin-like growth factor 1 receptor, IGF1-R, IGF-1R, CD221)], each heavy chain being fused to a scFv anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3)], *Homo sapiens* monoclonal antibody, bispecific tetravalent;
gamma1 heavy chain anti-IGFR1 fused to a scFv anti-ERBB3 (1-720) [*Homo sapiens* gamma1 heavy chain {(*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -*Homo sapiens* IGHG1*03v,G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451)}(1-451)-15-mer tris(tetraglycyl-seryl) linker (452-466) -scFv {(*Homo sapiens* VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4*01) [8.8.15] (467-588) -23-mer alanyl-seryl-threonyl-tetrakis(tetraglycyl-seryl) linker (589-611) -*Homo sapiens* V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720)}(467-720)],(225-214')-disulfide with kappa light chain anti-IGFR1 (1'-214') [*Homo sapiens* V-KAPPA(IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (231-231''':234-234'')-bisdisulfide

istiratumab

immunoglobuline G1-kappa anti-[*Homo sapiens* IGF1R (récepteur du facteur de croissance 1 analogue à l'insuline, IGF1-R, IGF-1R, CD221)], chaque chaîne lourde étant fusionnée à un scFv anti-[*Homo sapiens* ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3)], *Homo sapiens* anticorps monoclonal, bispécifique tétravalent; chaîne lourde gamma1 anti-IGFR1 fusionnée à un

scFv anti-ERBB3 (1-720) [chaîne lourde gamma1 *Homo sapiens* {(*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), charnière (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451)}(1-451) -15-mer tris(tétraglycyl-séryl) linker (452-466)-scFv {(*Homo sapiens* VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanyl-séryl-thréonyl-tétrakis(tétraglycyl-séryl) linker (589-611) -*Homo sapiens* V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glycyl (720)}(467-720)], (225-214')-disulfure avec la chaîne légère kappa anti-IGFR1 (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (231-231'':234-234'')-bisdisulfure

istiratumab

inmunoglobulina G1-kappa anti-[*Homo sapiens* IGF1R (receptor del factor de crecimiento 1 análogo a la insulina, IGF1-R, IGF-1R, CD221)], cada cadena pesada estando fusionada con un scFv anti-[*Homo sapiens* ERBB3 (receptor tirosina-proteína kinasa erbB-3, HER3)], *Homo sapiens* anticuerpo monoclonal, biespecífico tetravalente;
cadena pesada gamma1 anti-IGFR1 fusionada con un scFv anti-ERBB3 (1-720) [cadena pesada gamma1 *Homo sapiens* {(*Homo sapiens* VH (IGHV3-23*01 (90.80%) -(IGHD) -IGHJ4*01 L123>T (117))[8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219)(123-220), bisagra (221-235), CH2 (236-345), CH3 E12 (361), M14 (363) (346-450), CHS K2>del (451))(123-451)}(1-451) -15-mer tris(tetraglicil-seril) espaciador (452-466)-scFv {(*Homo sapiens* VH (IGHV3-9*01 (92.90%) -(IGHD) -IGHJ4-01) [8.8.15](467-588) -23-mer alanil-seril-treonil-tetrakis(tetraglicil-seril) espaciador (589-611) -*Homo sapiens* V-LAMBDA (IGLV3-19*01 (94.80%) -IGLJ3*02 L124>V (716)) [6.3.11] (612-719) -glicil (720)}(467-720)], (225-214')-disulfuro con la cadena ligera kappa anti-IGFR1 (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-12*01 (90.50%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLQSGGG LVQPGGSLRL SCAASGFMFS RYPMHWVRQA PGKGLEWVGS   5C
ISGSGGATPY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDF  10C
YQILTGNAFD YWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL  15C
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT  20C
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP  25C
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ  30C
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE  35C
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP  40C
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP  45C
GGGGGSGGGG SGGGGSQVQL VQSGGGLVQP GGSLRLSCAA SGFTFDDYAM  50C
HWVRQAPGKG LEWVAGISWD SGSTGYADSV KGRFTISRDN AKNSLYLQMN  55C
SLRAEDTALY YCARDLGAYQ WVEGFDYWGQ GTLVTVSSAS TGGGGSGGGG  60C
SGGGGSGGGG SSYELTQDPA VSVALGQTVR ITCQGDSLRS YYASWYQQKP  65C
GQAPVLVIYG KNNRPSGIPD RFSGSTSGNS ASLTITGAQA EDEADYYCNS  70C
RDSPGNQWVF GGGTKVTVLG                                   72C
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASLGDRVT ITCRASQGIS SYLAWYQQKP GKAPKLLIYA   5C
KSTLQSGVPS RFSGSGSGTD FTLTISSLQP EDSATYYCQQ YWTFPLTFGG  10C
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV  15C
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG  20C
LSSPVTKSFN RGEC                                         21C
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 149-205 266-326 372-430 488-562 633-698
22"-96" 149"-205" 266'-326" 372"-430" 488"-562" 633"-698"
Intra-L (C23-C104) 23'-88" 134'-194'
23"'-88"' 134"'-194"'
Inter-H-L (h 5-CL 126) 225-214' 225"-214"'
Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ladiratuzumabum #	
ladiratuzumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229'':232-232'')-bisdisulfide
ladiratuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229'':232-232'')-bisdisulfure
ladiratuzumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores de soluto, miembro 6 de la familia 39 (transportador de zinc) de los transportadores de soluto, LIV-1)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW  50
IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN 100
AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR  50
PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100
YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L (h 5-CL 126) 223-219' 223"-219'"
Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

ladiratuzumabum vedotinum #

ladiratuzumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), hinge (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimer (229-229":232-232")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker

For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

ladiratuzumab védotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* SLC39A6 (membre 6 de la famille 39 des transporteurs de soluté, membre 6 de la famille 39 (transporteur d'ion métal) des transporteurs de soluté, membre 6 de la famille 39 (transporteur du zinc) des transporteurs de soluté, LIV-1)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), charnière (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfure avec la chaîne légère kappa

(1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dimère (229-229'':232-232'')-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC)

Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

ladiratuzumab vedotina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SLC39A6 (miembro 6 de la familia 39 de los transportadores de soluto, miembro 6 de la familia 39 (transportador del ión metal) de los transportadores del soluto, miembro 6 de la familia 39 (transportador del zinc) de los transportadores del soluto, LIV-1)], anticuerpo monoclonal humanizado conjugado con la auristatina E;
cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV1-2*02 (87.60%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 K120 (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*02 (89.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; dímero (229-229'':232-232'')-bisdisulfuro; conjugado, con 4 restos cisteinil, por término medio, con monometilauristatina E (MMAE), mediante un enlace de tipo maleimidocaproil-valil-citrulinil-p-aminobenziloxicarbonil (mc-val-cit-PABC)

Para la fracción *vedotina, pueden referirse al documento "INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGLTJE DYYMHWVRQA PGQGLEWMGW  50
IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN 100
AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRJP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPFV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR  50
PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP 100
YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L (h 5-CL 126)* 223-219' 223"-219'"
Inter-H-H (h 11, h 14)* 229-229" 232-232"

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

lanacogenum vosiparvovecum #

lanacogene vosiparvovec	Non-replicating recombinant adeno-associated virus type 5 (AAV5) vector containing a codon-optimised of the wild type human coagulation factor IX (F9, FIX) gene under the control of the liver promoter 1 (LP1).
lanacogène vosiparvovec	vecteur viral adéno-associé recombinant de type 5 (AAV5) non-répliquant contenant une version avec des codons optimisés du gène du facteur IX de coagulacion de type sauvage (F9, FIX) humain sous le contrôle du promoteur LP1 des cellules hépatiques.
lanacogén vosiparvovec	Vector del Virus Adeno-asociado de serotipo 5 (AAV5) recombinante, no replicativo, que contiene una versión con codones optimizados del gen del factor de coagulación IX humano (F9, FIX) bajo el control del promotor hepático 1 (LP1).

lazertinibum

lazertinib	*N*-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide
lazertinib	*N*-{5-[(4-{4-[(diméthylamino)méthyl]-3-phényl-1*H*-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-méthoxy-2-(morpholin-4-yl)phényl}prop-2-enamide
lazertinib	*N*-{5-[(4-{4-[(dimetilamino)metil]-3-fenil-1*H*-pirazol-1-il}pirimidin-2-il)amino]-4-metoxi-2-(morfolin-4-il)fenil}prop-2-enamida

$C_{30}H_{34}N_8O_3$



leflutrozolum

leflutrozole	4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)methylene]dibenzonitrile
léflutrozole	4,4'-[fluoro(1*H*-1,2,4-triazol-1-yl)méthylène]dibenzonitrile
leflutrozol	4,4'-[fluoro(1*H*-1,2,4-triazol-1-il)metileno]dibenzonitrilo

$C_{17}H_{10}FN_{55}$



lifirafenibum

lifirafenib

5-({(1*R*,1a*S*,6b*R*)-1-[5-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1a,6b-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifiraféníb

5-({(1*R*,1a*S*,6b*R*)-1-[5-(trifluorométhyl)-1*H*-benzimidazol-2-yl]-1a,6b-dihydro-1*H*-cyclopropa[*b*][1]benzofuran-5-yl}oxy)-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

lifirafenib

5-({(1*R*,1a*S*,6b*R*)-1-[5-(trifluorometil)-1*H*-benzimidazol-2-il]-1a,6b-dihidro-1*H*-ciclopropa[*b*][1]benzofuran-5-il}oxi)-3,4-dihidro-1,8-naftiridin-2(1*H*)-ona

$C_{25}H_{17}F_3N_4O_3$



lonapegsomatropinum #

lonapegsomatropin

human somatotropin (growth hormone, GH) produced in *Escherichia coli*, conjugated to a multi-arm polyethylene glycol carrier molecule;

somatotropin (human), produced by *Escherichia coli*, $N^{6.Lys}$-substituted with one ({(1*RS*)-5-[bis(6-{[(3*RS*)-1-{3-[(3-{(2*RS*)-2,3-bis[ω-methoxypoly(oxyethylene)$_n$-α-yl]propoxy}propyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl]sulfanyl}hexyl)amino]-1-[4-({[3-(dimethylamino)propyl](methyl)carbamoyl}oxy)phenyl]-5-oxopentyl}oxy)carbonyl group

lonapegsomatropine

somatotropine humaine (hormone de croissance, GH) produite par *Escherichia coli*, conjuguée à une molécule transporteur multi-bras de polyéthylène glycol;

somatotropine (humaine), produite par *Escherichia coli*, substituée en $N^{6.Lys}$ par un groupe ({(1*RS*)-5-[bis(6-{[(3*RS*)-1-{3-[(3-{(2*RS*)-2,3-bis[ω-méthoxypoly(oxyéthylène)$_n$-α-yl]propoxy}propyl)amino]-3-oxopropyl}-2,5-dioxopyrrolidin-3-yl]sulfanyl}hexyl)amino]-1-[4-({[3-(diméthylamino)propyl](méthyl)carbamoyl}oxy)phényl]-5-oxopentyl}oxy)carbonyle

lonapegsomatropina

somatotropina humana (hormona de crecimiento, GH) producida por *Escherichia coli*, conjugada a una molécula transportadora multi-bras de polietileno glicol;

somatotropina (humana), producida por *Escherichia coli*, sustituida en $N^{6.Lys}$ por un grupo ({(1*RS*)-5-[bis(6-{[(3*RS*)-1-{3-[(3-{(2*RS*)-2,3-bis[ω-metoxipoli(oxietileno)$_n$-α-il]propoxi}propil)amino]-3-oxopropil}-2,5-dioxopirrolidin-3-il]sulfanil}hexil)amino]-1-[4-({[3-(dimetilamino)propil](metil)carbamoil}oxi)fenil]-5-oxopentil}oxi)carbonilo

Sequence / Séquence / Secuencia

```
FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT  50
SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS 100
LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFK QTYSKFDTNS 150
HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F          191
```

Disulfide bridges location / Position des ponts disulfure / Posición de los puentes disulfuro
53-165 182-189

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales



loncastuximabum #

loncastuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody;
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dimer (229-229'':232-232'')-bisdisulfide

loncastuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dimère (229-229'':232-232'')-bisdisulfure

loncastuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNWMHWVKQA PGQGLEWIGE  50
IDPSDSYTNY NQNFQGKAKL TVDKSTSTAY MEVSSLRSDD TAVYYCARGS 100
NPYYYAMDYW GQGTSVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAI MSASPGERVT MTCSASSGVN YMHWYQQKPG TSPRRWIYDT  50
SKLASGVPAR FSGSGSGTSY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNNFYPRE AKVQWKVDNA 150
LQSGNSQESV TEQDSKDSTY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS 200
PVTKSFNRGE C                                           211
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-87' 131'-191'
23'"-87'" 131'"-191'"
Inter-H-L (h 5-CL 126) 223-211' 223"-211'"
Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

loncastuximabum tesirinum #

loncastuximab tesirine

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD19 (B lymphocyte surface antigen B4, Leu-12)], chimeric monoclonal antibody conjugated to the pyrrolobenzodiazepine (PBD) dimer SCX;
gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120**>**K (217) (121-218), hinge (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfide with kappa light chain (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3 A45.1 (150), V101 (188) (105'-211')]; dimer (229-229''':232-232''')-bisdisulfide;conjugated, on an average of 2 cysteines, to the pyrrolobenzodiazepine (PBD) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsin B cleavage site) maleimide type linker containing a spacer PEG (n=8)

For the *tesirine* part, please refer to the prop.INN List 113, published in *the WHO Drug Information, Vol.29, No.2, 2015.*

loncastuximab tésirine

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD19 (antigène de surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal chimérique conjugué au dimère de pyrrolobenzodiazépine (PDB) SCX;
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120**>**K (217) (121-218), charnière (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfure avec la

	chaîne légère kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dimère (229-229'':232-232'')-bisdisulfure; conjugué, sur 2 cystéines en moyenne, au dimère de pyrrolobenzodiazépine (PBD) SCX, via un linker clivable (dipeptide valine-alanine clivable par la cathepsine B) de type maléimide et comprenant un espaceur PEG (n=8) Pour la partie *tésirine*, veuillez-vous référer à la Liste 113 des DCI prop, publiée dans le *WHO Drug Information, Vol.29, No.2, 2015.*
loncastuximab tesirina	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD19 (antígeno de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal quimérico conjugado con el dímero de pirrolobenzodiazepina (PDB) SCX; cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-69*02 (85.70%) -(IGHD) -IGHJ4*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120**>**K (217) (121-218), bisagra (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-211')-disulfuro con la cadena ligera kappa (1'-211') [*Mus musculus* V-KAPPA (IGKV4-70*01 (91.40%) -IGKJ1*01) [5.3.7] (1'-104') -*Homo sapiens* IGKC*01, Km3(105'-211')]; dímero (229-229'':232-232'')-bisdisulfuro; conjugado, en una media de 2 cisteinil, con el dímero de pirrolobenzodiazepina (PBD) SCX, mediante un conector escindible (dipéptido valina-alanina escindible por la catepsina B) de tipo maleimida y comprende un espaciador PEG (n=8) Para la fracción *tesirina* se puede referir a la Lista 113 de DCI prop., publicada en el *WHO Drug Information, Vol.29, No.2, 2015.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQPGAE VVKPGASVKL SCKTSGYTFT SNWMHWVKQA PGQGLEWIGE  50
IDPSDSYTNY NQNFQGKAKL TVDKSTSTAY MEVSSLRSDD TAVYYCARGS 100
NPYYYAMDYW GQGTSVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAI MSASPGERVT MTCSASSGVN YMHWYQQKPG TSPRRWIYDT  50
SKLASGVPAR FSGSGSGTSY SLTISSMEPE DAATYYCHQR GSYTFGGGTK 100
LEIKRTVAAP SVFIFPPSDE QLKSGTASVV CLLNNFYPRE AKVQWKVDNA 150
LQSGNSQESV TEQDSKDSTY SLSSTLTLSK ADYEKHKVYA CEVTHQGLSS 200
PVTKSFNRGE C                                           211
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22''-96'' 147''-203'' 264''-324'' 370''-428''

Intra-L (C23-C104) 23'-87' 131'-191'
23'''-87''' 131'''-191'''

Inter-H-L (h5-CL126)* 223-211' 223''-211''

Inter-H-H (h11, h14) 229-229'' 232-232''

*One or two of the inter-chain disulfide bridges are not present, an average of 2 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Un ou deux des ponts disulfures inter-chaînes ne sont pas présents, 2 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 2 cisteinil conjugados con sendos enlaces tioéter, a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300''

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

lumasiranum

lumasiran

{(*2S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis-({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl}methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate duplex with *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(5'→3')-2'-*O*-methyl-*P*-thiocytidylyl-(5'→3')-2'-*O*-methylcytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methylguanylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine

lumasiran

hydrogéno-*tout-P-ambo*-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-désoxy-2'-fluorouridylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-désoxy-2'-fluorocytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de {(*2S*,4*R*)-1-{1-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis-({3-[(3-{5-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-6,10,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl}méthyle duplex avec *tout-P-ambo*-2'-*O*-méthyl-*P*-thioadénylyl-(5'→3')-2'-*O*-méthyl-*P*-thiocytidylyl-(5'→3')-2'-*O*-méthylcytidylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-désoxy-2'-fluoroadénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthylguanylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-méthyluridylyl-(5'→3')-2'-*O*-méthyladénylyl-(5'→3')-2'-*O*-méthyl-*P*-thiouridylyl-(5'→3')-2'-désoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-*O*-méthyluridine

lumasirán

hydrógeno-*todo*-*P*-*ambo*-2'-*O*-metil-*P*-tioguanilil-(3'→5')-2'-*O*-metil-*P*-tioadenylyl-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-desoxi-2'-fluorouridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metil-3'-adenilato de {(*2S*,*4R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis-({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi}metil)-6,10,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il}metilo dúplex con *todo*-*P*-*ambo*-2'-*O*-metil-*P*-tioadenilil-(5'→3')-2'-*O*-metil-*P*-tiocitidilil-(5'→3')-2'-*O*-metilcitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metilguanilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-*O*-metiluridilil-(5'→3')-2'-*O*-metiladenilil-(5'→3')-2'-*O*-metil-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-*O*-metiluridina

$C_{530}H_{712}F_{10}N_{173}O_{320}P_{43}S_6$



X : 2'-deoxy-2'-fluoro-X / **X** : 2'-désoxy-2'-fluoro-X
X : 2'-*O*-methyl-X / X : 2'-*O*-méthyl-X



mardepodectum

mardepodect

2-({4-[1-methyl-4-(pyridin-4-yl)-1*H*-pyrazol-3-yl]phenoxy}methyl)quinoline

mardépodect

2-({4-[1-méthyl-4-(pyridin-4-yl)-1*H*-pyrazol-3-yl]phénoxy}méthyl)quinoléine

mardepodect

2-({4-[1-metil-4-(piridin-4-il)-1*H*-pirazol-3-il]fenoxi}metil)quinoleína

$C_{25}H_{20}N_4O$



miladem etanum

miladem etan (3'*R*,4'*S*,5'*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide

miladémétan (3'*R*,4'*S*,5'*R*)-*N*-[(3*R*,6*S*)-6-carbamoyloxan-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-diméthyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide

milademetán (3'*R*,4'*S*,5'*R*)-*N*-[(3*R*,6*S*)-6-carbamoiloxan-3-il]-6''-cloro-4'-(2-cloro-3-fluoropiridin-4-il)-4,4-dimetil-2''-oxo-1'',2''-dihidrodispiro[ciclohexano-1,2'-pirrolidina-3',3''-indol]-5'-carboxamida

$C_{30}H_{34}Cl_2FN_5O_4$



minesapridum

minesapride 4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacetyl)piperidin-4-yl]methyl}morpholin-2-yl]methyl}-2-methoxybenzamide

minésapride 4-amino-5-chloro-*N*-{[(2*S*)-4-{[1-(hydroxyacétyl)pipéridin-4-yl]méthyl}morpholin-2-yl]méthyl}-2-méthoxybenzamide

minesaprida 4-amino-5-cloro-*N*-{[(2*S*)-4-{[1-(hidroxiacetil)piperidin-4-il]metil}morfolin-2-il]metil}-2-metoxibenzamida

$C_{21}H_{31}ClN_4O_5$



miralimogenum ensolisbacum #

miralimogene ensolisbac	Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the *Lm* ActA protein (ActAN100) and amino acids 35-622 of human mesothelin (MSLN) protein, under the control of the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 2306 bp inserted at the *Lm inlB* (internalin B) locus
miralimogène ensolisbac	souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) avec double deletion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 2306 paires de bases insérée sur le locus de *Lm inlB* (internaline B).
miralimogén ensolisbac	Cepa viva atenuada recombinante, con doble deleción, de *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 2306 pares de bases insertado en el locus de *Lm inlB* (internalina B).

mirikizumabum #

mirikizumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19)], humanized monoclonal antibody; gamma4 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (221-221'':224-224'')-bisdisulfide
mirikizumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL-23 sous-unité p19, IL23p19)], anticorps monoclonal humanisé;

chaîne lourde gamma4 (1-441) [VH humanisé (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (221-221'':224-224'')-bisdisulfure

mirikizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL-23 subunidad p19, IL23p19)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-441) [VH humanizado (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD) -IGHJ6*01) [8.8.8] (1-115) -*Homo sapiens* IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 F1.3>A (229), L1.2>A (230) (226-335), CH3 (336-440), CHS K>del (441)) (116-441)], (129-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (221-221'':224-224'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYKFT RYVMHWVRQA PGQGLEWMGY  50
INPYNDGTNY NEKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNW 100
DTGLWGQGTT VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEAA GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL G          441
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASDHIL KFLTWYQQKP GKAPKLLIYG  50
ATSLETGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQM YWSTPFTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 142-198 256-316 362-420
22''-96'' 142''-198'' 256''-316'' 362''-420''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (h 5-CL 126) 129-214' 129''-214'''
Inter-H-H (h 11, h 14) 221-221'' 224-224''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
292, 292''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mosunetuzumabum #
mosunetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon) and*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-CD3E (1-449) [humanized VH (*Homo sapiens* IGHV1-3*01 (82.70%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), hinge (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfide with kappa light chain anti-CD3E (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; gamma1 heavy chain anti-MS4A1 (1-452) [humanized VH (*Homo sapiens* IGHV3-23*04 (81.60%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), hinge (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfide with kappa light chain anti-MS4A1 (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimer (228-231":231-234")-bisdisulfide
mosunétuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon) et *Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-CD3E (1-449) [VH humanisé (*Homo sapiens* IGHV1-3*01 (82.70%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), charnière (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfure avec la chaîne légère kappa anti-CD3E (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')]; chaîne lourde gamma1 anti-MS4A1 (1-452) [VH humanisé (*Homo sapiens* IGHV3-23*04 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), charnière (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfure avec la chaîne légère kappa anti-MS4A1 (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')]; dimère (228-231":231-234")-bisdisulfure
mosunetuzumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD3E (CD3 epsilon) y *Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal humanizado, biespecífico;

cadena pesada gamma1 anti-CD3E (1-449) [VH humanizado (*Homo sapiens* IGHV1-3*01 (82.70%) -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (216) (120-217), bisagra (218-232), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368) / L24>A (370) / Y86>V (409) (hole) (343-447), CHS (448-449)) (120-449)], (222-219')-disulfuro con la cadena ligera kappa anti-CD3E (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (91.80%) -IGKJ1*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')];
cadena pesada gamma1 anti-MS4A1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-23*04 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (219) (123-220), bisagra (221-235), CH2 N84.4>G (302) (236-345), CH3 E12 (361), M14 (363), T22>W (371) (knob) (346-450), CHS (451-452)) (123-452)], (225-213')-disulfuro con la cadena ligera kappa anti-MS4A1 (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.50%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 A45.1 (152), V101 (190) (107'-213')];
dímero (228-231'':231-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-CD3E)

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT NYYIHWVRQA PGQGLEWIGW  50
IYPGDGNTKY NEKFKGRATL TADTSTSTAY LELSSLRSED TAVYYCARDS 100
YSNYYFDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYGS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera (anti-CD3E)

```
DIVMTQSPDS LAVSLGERAT INCKSSQSLL NSRTRKNYLA WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCTQSFIL 100
RTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-MS4A1)

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYNMHWVRQA PGKGLEWVGA  50
IYPGNGDTSY NQKFKGRFTI SVDKSKNTLY LQMNSLRAED TAVYYCARVV 100
YYSNSYWYFD VWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YGSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL WCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                     452
```

Light chain / Chaîne légère / Cadena ligera (anti-MS4A1)

```
DIQMTQSPSS LSASVGDRVT ITCRASSSVS YMHWYQQKPG KAPKPLIYAP  50
SNLASGVPSR FSGSGSGTDF TLTISSLQPE DFATYYCQQW SFNPPTFGQG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427	
	22''-96''	149''-205''	266''-326''	372''-430''	
Intra-L (C23-C104)	23'-94'	139'-199'			
	23'''-87'''	133'''-193'''			
Inter-H-L (h 5-CL 126)	222-219'	225''-213'''			
Inter-H-H (h 11, h 14)	228-231''	231-234''			

nadofaragenum firadenovecum #

nadofaragene firadenovec — Replication-deficient adenovirus type 5 (Ad5) vector encoding the human interferon alpha 2 (IFNA2, interferon alpha-2b) gene under the control of the cytomegalovirus (CMV) immediate-early enhancer/promoter.

nadofaragène firadénovec — vecteur adénoviral de type 5 (Ad5) à la réplication déficiente, codant pour le gène de l'interféron alpha 2 (IFNA2, interféron alpha-2b) humain sous le contrôle de l'activateur/promoteur immédiat-précoce du cytomégalovirus (CMV).

nadofaragén firadenovec — Vector de Adenovirus tipo 5 (Ad5) deficiente de replicación, que codifica para el gen del interferón alfa 2 humano (IFNA2, inteferón alfa-2b) bajo el control del promotor/*enhancer* inmediato-temprano del citomegalovirus (CMV).

namodenosonum

namodenoson — 1-(2-chloro-6-{[(3-iodophenyl)methyl]amino}-9*H*-purin-9-yl)-1-deoxy-*N*-methyl-β-D-ribofuranuronamide

namodénoson — 1-(2-chloro-6-{[(3-iodophényl)methyl]amino}-9*H*-purin-9-yl)-1-désoxy-*N*-méthyl-β-D-ribofuranuronamide

namodenosón — 1-(2-cloro-6-{[(3-iodofenil)metil]amino}-9*H*-purin-9-il)-1-desoxi-*N*-metil-β-D-ribofuranuronamida

$C_{18}H_{18}ClIN_6O_4$



nangibotidum

nangibotide — human trem-like transcript 1 protein (TLT-1, triggering receptor expressed on myeloid cells-like protein 1) (79-90)-peptide 12-amide:
L-leucyl-L-glutaminyl-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methioninamide

nangibotide — protéine transcrit 1 semblable au trem humaine (TLT-1, protéine 1 semblable au récepteur déclenchant exprimé par les cellules myéloïdes) (79-90)-peptide 12-amide:
L-leucyl-L-glutaminyl-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cystéinyl-L-méthioninamide

nangibotida — proteína transcrito 1 parecido al trem humano (TLT-1, proteína 1 parecida al receptor desencadenante expresado por las células mieloides) (79-90)-péptido 12-amida:

L-leucil-L-glutaminil-L-α-glutamil-L-α-glutamil-L-α-aspartil-L-alanilglicil-L-α-glutamil-L-tirosilglicil-L-cisteinil-L-metioninamida

$C_{54}H_{82}N_{14}O_{22}S_2$

H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH_2
12

olinciguatum

olinciguat — (2*R*)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide

olinciguat — (2*R*)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophényl)méthyl]-5-(1,2-oxazol-3-yl)-1*H*-pyrazol-3-yl}pyrimidin-4-yl)amino]méthyl}-2-hydroxypropanamide

olinciguat — (2*R*)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorofenil)metil]-5-(1,2-oxazol-3-il)-1*H*-pirazol-3-il}pirimidin-4-il)amino]metil}-2-hidroxipropanamida

$C_{21}H_{16}F_5N_7O_3$



olorofimum

olorofim — 2-(1,5-dimethyl-3-phenyl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)piperazin-1-yl]phenyl}-2-oxoacetamide

olorofim — 2-(1,5-diméthyl-3-phényl-1*H*-pyrrol-2-yl)-*N*-{4-[4-(5-fluoropyrimidin-2-yl)pipérazin-1-yl]phényl}-2-oxoacétamide

olorofim — 2-(1,5-dimetil-3-fenil-1*H*-pirrol-2-il)-*N*-{4-[4-(5-fluoropirimidin-2-il)piperazin-1-il]fenil}-2-oxoacetamida

$C_{28}H_{27}FN_6O_2$



omberacetamum

omberacetam	ethyl 1-phenylacetyl-L-prolylglycinate
ombéracétam	1-phénylacétyl-L-prolylglycinate d'éthyle
omberacetam	1-fenilacetil-L-prolilglicinato de etilo

$C_{17}H_{22}N_2O_4$



onasemnogenum abeparvovecum #

onasemnogene abeparvovec	Non-replicating recombinant self-complementary (sc) adeno-associated viral serotype 9 (AAV9) vector containing the cDNA of the survival of motor neuron 2 (SMN2) gene under the control of the hybrid cytomegalovirus (CMV) enhancer/chicken beta-actin promoter (CBA).
onasemnogène abéparvovec	vecteur viral adéno-associé recombinant de sérotype 9 (**r**AAV9) non-répliquant et auto-complémentaire, contenant l'ADNc du gène de survie des motoneurones 2 (SMN2) sous le contrôle de l'hybride de l'activateur du cytomégalovirus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).
onasemnogén abeparvovec	vector del virus adeno-asociado de serotipo 9 (AAV9) recombinante, no replicativo y auto complementario, que contiene el cDNA del gen de la supervivencia de neuronas motoras 2 (SMN2) bajo el control del híbrido del *enhancer* de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).

opaganibum

opaganib	3-(4-chlorophenyl)-*N*-[(pyridin-4-yl)methyl]adamantane-1-carboxamide
opaganib	3-(4-chlorophényl)-*N*-[(pyridin-4-yl)méthyl]adamantane-1-carboxamide
opaganib	3-(4-clorofenil)-*N*-[(piridin-4-il)metil]adamantano-1-carboxamida

$C_{23}H_{25}ClN_2O$



opiranserinum

opiranserin	4-butoxy-*N*-{[4-(dimethylamino)oxan-4-yl]methyl}-3,5-dimethoxybenzamide
opiransérine	4-butoxy-*N*-{[4-(diméthylamino)oxan-4-yl]méthyl}-3,5-diméthoxybenzamide
opiranserina	4-butoxi-*N*-{[4-(dimetilamino)oxan-4-il]metil}-3,5-dietoxibenzamida

$C_{21}H_{34}N_2O_5$



opolimogenum capmilisbacum #

opolimogene capmilisbac	Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) expressing three recombinant fusion proteins as follows: (i) the N-terminal 100 amino acids of the *Lm* ActA (actin-assembly inducing protein precursor) protein (Act*A*N100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and human protein SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), under the control of the *Lm actA* promoter, and contained within an expression cassette of 1434 bp inserted at the *actA* locus; (ii) the N-terminal 100 amino acids of the *Lm* ActA protein (Act*A*N100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 33-386 of human prostatic acid phosphatase (PAP), under the control the *Lm actA* promoter, and contained within an expression cassette of 2057 bp inserted at the *inlB* (internalin B) locus; (iii) the N-terminal 100 amino acids of the *Lm* ActA protein (Act*A*N100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 11-234 of human homeobox protein Nkx-3.1 (NKX3-1) plus amino acids 1-20, 44-138 and 169-750 of human glutamate carboxypeptidase 2 (also known as folate hydrolase 1 (FOLH1), prostate-specific membrane antigen (PSMA)), under the control the *Lm actA* promoter, and contained within an expression cassette of 4984 bp at the *tRNA*^{Arg} locus.
opolimogène capmilisbac	Souche vivante atténuée recombinante de *Listeria monocytogenes (Lm ΔactA/ΔinlB)* avec double délétion, exprimant les trois protéines de fusion suivantes: (i) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine) (Act*A*N100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et la protéine humaine SSX2 (sarcome synovial, point de cassure X2, aussi connu comme antigène cancer/testicule 5.2 (CT5.2), antigène tumoral HOM-MEL-40), sous le contrôle du promoteur *Lm actA*, et contenu dans une cassette d'expression de 1434 paires de bases insérée sur le locus de *actA*;

	(ii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA (*ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 33-386 de la phosphatase acide prostatique (PAP) humaine, sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 2057 paires de bases insérée sur le locus de *inlB* (internaline B); (iii) les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm actA (*ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 11-234 de la protéine homéoboîte humaine Nkx-3.1 (NKX3-1) plus les acides aminés 1-20, 44-138, 169-750 de la glutamate caroxypeptidase 2 humaine (folate hydrolase 1, FOLH1, antigène membranaire spécifique de la prostate, PSMA) sous le contrôle du promoteur *Lm actA*, contenu dans une cassette d'expression de 4984 paires de bases insérée sur le locus de *Lm tRNA*^{Arg}.
opolimogén capmilisbac	Cepa viva atenuada recombinante, con doble deleción, de *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) que expresa las siguientes tres proteínas recombinantes de fusión: (i) los 100 amino ácidos N-terminales de la proteína *Lm* ActA (precursor de la proteína inductora del ensamblaje de la actina) (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y la proteína humana SSX2 (synovial sarcoma, X breakpoint 2, also known as cancer/testis antigen 5.2 (CT5.2), tumor antigen HOM-MEL-40), bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 1434 pares de bases insertado en el locus de *actA*; (ii) los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 33-386 de la fosfatasa ácida prostática (PAP) humana, bajo el control del promotor de *Lm actA*, y contenido dentro de un casete de expresión de 2057 pares de bases insertado en el locus de*inlB* (internalina B); (iii) los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 11-234 de la proteína *homeobox* humana Nkx-3.1 (NKX3-1) más los amino ácidos 1-20, 44-138 y 169-750 de la glutamato carboxipeptidasa 2 humana (también conocida como folato hidrolasa 1 (FOLH1), antígeno de membrana específico de próstata (PSMA)), bajo el control del promotor de *Lm actA* y contenido dentro de un casete de expresión de 4984 pares de bases insertado en el locus de *Lm tRNA*^{Arg}.
pamiparibum	
pamiparib	(10a*R*)-2-fluoro-10a-methyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[*def*]cyclopenta[*a*]fluoren-4(7*H*)-one

pamiparib	(10a*R*)-2-fluoro-10a-méthyl-5,8,9,10,10a,11-hexahydro-5,6,7a,11-tétraazacyclohepta[*def*]cyclopenta[*a*]fluorén-4(7*H*)-one
pamiparib	10a*R*)-2-fluoro-10a-metil-5,8,9,10,10a,11-hexahidro-5,6,7a,11-tetraazaciclohepta[*def*]ciclopenta[*a*]fluoren-4(7*H*)-ona

$C_{16}H_{15}FN_4O$



parsaclisibum

parsaclisib	(4*R*)-4-{3-[(1*S*)-1-(4-amino-3-methyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl}pyrrolidin-2-one
parsaclisib	(4*R*)-4-{3-[(1*S*)-1-(4-amino-3-méthyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl)éthyl]-5-chloro-2-éthoxy-6-fluorophényl}pyrrolidin-2-one
parsaclisib	(4*R*)-4-{3-[(1*S*)-1-(4-amino-3-metil-1*H*-pirazolo[3,4-*d*]pirimidin-1-il)etil]-5-cloro-2-etoxi-6-fluorofenil}pirrolidin-2-ona

$C_{20}H_{22}ClFN_6O_2$



pegdarbepoetinum beta #

pegdarbepoetin beta	N-terminal pegylated human erythropoietin fragment, mutated, produced in Chinese hamster ovary (CHO) cells, glycoform beta; [Ala^{30}>Asn,His^{32}>Thr,Pro^{87}>Val,Trp^{88}>Asn,Pro^{90}>Thr]erythropoietin (human)-(1-165)-peptide, produced in Chinese hamster ovary (CHO) cells, glycoform beta, chemically modified on Ala^{1}-*N* with a 4-[ω-methoxypoly(oxyethylene)$_n$-α-yl]butyl group (n ~ 682).
pegdarbépoétine bêta	fragment d'érythropoïétine humaine pégylé à l'extrémité N-terminale, modifié, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta;

[Ala^{30}>Asn,His^{32}>Thr,Pro^{87}>Val,Trp^{88}>Asn,Pro^{90}>Thr]érythropoïétine (humaine)-(1-165)-peptide, produit par des cellules ovariennes de hamster chinois (CHO), glycoforme bêta, chimiquement modifié sur l'Ala^{1}-*N* avec un groupe 4-[ω-méthoxypoly(oxyéthylène)$_n$-α-yl]butyle (n ~ 682).

pegdarbepoetina beta

fragmente de eritropoyetina humana pegilado en la extremidad N-terminale, modificado, producido por las células ováricas de hamster chino (CHO), glicoforma beta;

[Ala^{30}>Asn,His^{32}>Thr,Pro^{87}>Val,Trp^{88}>Asn,Pro^{90}>Thr]eritropoyetina (humana)-(1-165)-péptido, producido por las células ováricas de hamster chino (CHO), glicoforma beta, químicamente modificado sobre la Ala^{1}-*N* con un groupo 4-[ω-metoxipoli(oxietileno)$_n$-α-il]butilo (n ~ 682).

$C_{805}H_{1310}N_{228}O_{245}S_5(C_2H_4O)_n$

Sequence / Séquence / Secuencia

APPRLICDSR VLERYLLEAK EAENITTGCN ETCSLNENIT VPDTKVNFYA 50
WKRMEVGQQA VEVWQGLALL SEAVLRGQAL LVNSSQVNET LQLHVDKAVS 100
GLRSLTTLLR ALGAQKEAIS PPDAASAAPL RTITADTFRK LFRVYSNFLR 150
GKLKLYTGEA CRTGD 165

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
7-161 29-33

Modified residue / Résidu modifié / Resto modificado

A (1) = *N*-pegAla



Glycosylation site (N, S) / Site de glycosylation (N, S) / Posición de glicosilatión (N, S)
Asn-24 Asn-30 Asn-38 Asn-88 Asn-80 Ser-126

pegilodecakinum #
pegilodecakin

N-terminal pegylated human interleukin 10 (IL10) analogue, with an added methionine at the N-terminus, dimer, produced in recombinant *Escherichia coli*; *N*-{3-[ω-methoxypoly(oxyethylene)-α-yl]propyl}-L-methionyl-interleukin 10 (human), homodimer (non-covalent), produced in recombinant *Escherichia coli*

pégilodécakine

analogue de l'interleukine 10 humaine, pégylé en position N-terminale, avec l'ajout d'une méthionine en position N-terminale, dimère, produit par *Escherichia coli;* *N*-{3-[ω-méthoxypoly(oxyéthylène)-α-yl]propyl}-L-méthionyl-interleukine 10 (humaine), homodimère (non covalent), produit par *Escherichia coli*

pegilodecakina

análogo de la interleukina 10 humano , pegilado en posición N-terminal, con la ayuda de una metionina en posición N-terminal, dímero, producido por *Escherichia coli;* *N*-{3-[ω-metoxipoli(oxietileno)-α-il]propil}-L-metionil-interleukina 10 (humano), homodímero (no covalente), producido por *Escherichia coli*

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
                                                          M  0
SPGQGTQSEN SCTHFPGNLF NMLRDLRDAF SRVKTFFQMK DQLDNLLLKE  50
SLLEDFKGYL GCQALSEMIQ FYLEEVMPQA ENQDPDIKAH VNSLGENLKT 100
LRLRLRPCHR FLPCENKSKA VEQVKNAFNK LQEKGIYKAM SEFDIFINYI 150
EAYMTMKIRN                                              160
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
12-108 62-114

Modified residues / Résidus modifiés / Restos modificados

M
0, 0'
pegylated-L-methionine



pegzilarginasum #
pegzilarginase

pegylated human arginine amidinase (arginase I, EC=3.5.3.1), mutated, cobalt ions replacing native manganese ions, trimer, produced in *Escherichia coli*;

des-Met[1]-arginase-1 (human) dicobalt(II) complex, trimer, produced by *Escherichia coli*, substituted on an average of 8 to 16 primary amino groups of each protein monomer with [ω-methoxypoly(oxyethylene)$_n$-α-yl]acetyl groups (n ~ 120)

pegzilarginase

arginine amidinase humaine pégylée (arginase I, EC=3.5.3.1), modifiée, dans laquelle le manganèse est remplacé par du cobalt, trimère, produit par *Escherichia coli*;

dès-Mét[1]-arginase-1 (humaine) dicobalt(II) complexe, trimère, produit par *Escherichia coli*, substituée sur une moyenne de 8 sur 16 groupes amines primaires de chaque monomère de la protéine avec des groupes [ω-méthoxypoly(oxyéthylène)$_n$-α-yl]acétyles (n ~ 120)

pegzilarginasa

arginina amidinasa humana pegilada (arginasa I, EC=3.5.3.1), modificada, iones de cobalto que reemplazan iones de manganeso nativos, trímero, producido por *Escherichia coli*;

des-Met[1]-arginasa-1 (humana) dicobalto(II) complejo, trímero, producido por *Escherichia coli*, sustituida por una media de 8 a 16 grupos aminas primarias de cada monómero de la proteína con los grupos [ω-metoxipoli(oxietileno)$_n$-α-il]acetilos (n ~ 120)

Monomer sequence / Séquence du monomère / Secuencia del monómero

```
SAKSRTIGII GAPFSKGQPR GGVEEGPTVL RKAGLLEKLK EQECDVKDYG  50
DLPFADIPND SPFQIVKNPR SVGKASEQLA GKVAEVKKNG RISLVLGGDH 100
SLAIGSISGH ARVHPDLGVI WVDAHTDINT PLTTTSGNLH GQPVSFLLKE 150
LKGKIPDVPG FSWVTPCISA KDIVYIGLRD VDPGEHYILK TLGIKYFSMT 200
EVDRLGIGKV MEETLSYLLG RKKRPIHLSF DVDGLDPSFT PATGTPVVGG 250
LTYREGLYIT EEIYKTGLLS GLDIMEVNPS LGKTPEEVTR TVNTAVAITL 300
ACFGLAREGN HKPIDYLNPP K                                 321
```

Potential modified residues / Résidus modifiés potentiels / Restos modificados potenciales

S : pegylated L-serine



K : pegylated L-lysines





= R—

pemlimogenum merolisbacum #

pemlimogene merolisbac	Recombinant live-attenuated double-deleted (LADD) strain of *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) expressing a fusion protein comprising the N-terminal 100 amino acids of the Lm ActA protein (ActAN100), 5 tandem copies of a 21 amino acid fragment of human epidermal growth factor receptor variant III (EGFRvIII) and amino acids 35-622 of human mesothelin (MSLN), under the control the *Lm actA* (actin-assembly inducing protein precursor) promoter, and contained within an expression cassette of 3874 bp inserted at the *Lm tRNA*^{Arg} locus.
pemlimogène mérolisbac	Souche vivante atténuée recombinante de *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) avec double délétion, exprimant une protéine de fusion qui consiste en les 100 acides aminés à l'extrémité N-terminale de la protéine *Lm* ActA (ActAN100), 5 copies en tandem d'un fragment de 21 acides aminés de la variante III du récepteur du facteur de croissance épidermique humain (EGFRvIII) et les acides aminés 35-622 de la mésothéline humaine (MSLN), sous le contrôle du promoteur de *Lm actA* (précurseur de la protéine induisant l'assemblage de l'actine), et contenu dans une cassette d'expression de 3874 paires de bases insérée sur le locus de *Lm tRNA*^{Arg}.
pemlimogén merolisbac	Cepa viva atenuada recombinante, con doble deleción, de *Listeria monocytogenes* (*Lm* Δ*actA*/Δ*inlB*) que expresa una proteína de fusión consistente en los 100 amino ácidos N-terminales de la proteína *Lm* ActA (ActAN100), 5 copias en tándem de un fragmento de 21 amino ácidos de la variante III del receptor para el factor de crecimiento epidérmico humano (EGFRvIII) y los amino ácidos 35-622 de la mesotelina humana (MSLN), bajo el control del promotor de *Lm actA* (precursor de la proteína inductora del ensamblaje de la actina), y contenido dentro de un casete de expresión de 3874 pares de bases insertado en el locus de *Lm tRNA*^{Arg}

petesicatibum

petesicatib	(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-methyl-1*H*-pyrazol-4-yl)-2-(trifluromethyl)benzenesulfonyl]-1-[1-(trifluoromethyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide
pétésicatib	(2*S*,4*R*)-*N*-(1-cyanocyclopropyl)-4-[4-(1-méthyl-1*H*-pyrazol-4-yl)-2-(trifluorométhyl)benzènesulfonyl]-1-[1-(trifluorométhyl)cyclopropane-1-carbonyl]pyrrolidine-2-carboxamide
petesicatib	2*S*,4*R*)-*N*-(1-cianociclopropil)-4-[4-(1-metil-1*H*-pirazol-4-il)-2-(triflurometil)bencenosulfonil]-1-[1-(trifluorometil)ciclopropano-1-carbonil]pirrolidina-2-carboxamida

$C_{25}H_{23}F_6N_5O_4S$



pixatimodum

pixatimod	5α-cholestan-3β-yl 2,3,4,6-tetra-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-β-D-glucopyranoside
pixatimod	2,3,4,6-tétra-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-sulfo-β-D-glucopyranoside de 5α-cholestan-3β-yle
pixatimod	2,3,4,6-tetra-*O*-sulfo-α-D-glucopiranosil-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopi-ranosil-(1→4)-2,3,6-tri-*O*-sulfo-α-D-glucopiranosil-(1→4)-2,3,6-tri-*O*-sulfo-β-D-glucopiranósida de 5α-colestan-3β-ilo

$C_{51}H_{88}O_{60}S_{13}$



plocabulinum

plocabulin	(1*Z*,4*S*,6*Z*)-1-[(2*S*)-2-{(2*Z*,4*Z*,6*E*,8*S*)-8-[(2*S*)-5-methoxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-6-methylnona-2,4,6-trienamido}-3,3-dimethylbutanamido]octa-1,6-dien-4-yl carbamate
plocabuline	carbamate de (1*Z*,4*S*,6*Z*)-1-[(2*S*)-2-{(2*Z*,4*Z*,6*E*,8*S*)-8-[(2*S*)-5-méthoxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-6-méthylnona-2,4,6-triénamido}-3,3-diméthylbutanamido]octa-1,6-dien-4-yle
plocabulina	carbamato de (1*Z*,4*S*,6*Z*)-1-[(2*S*)-2-{(2*Z*,4*Z*,6*E*,8*S*)-8-[(2*S*)-5-metoxi-6-oxo-3,6-dihidro-2*H*-piran-2-il]-6-metilnona-2,4,6-trienamido}-3,3-dimetilbutanamido]octa-1,6-dien-4-ilo



prasinezumabum #

prasinezumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* SNCA (synuclein alpha, PARK1, PARK4, Parkinson disease (autosomal dominant, Lewy body) 4, alpha-synuclein, aSyn, non A4 component of amyloid precursor, NACP)], humanized monoclonal antibody;
gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), hinge (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (225-225'':228-228'')-bisdisulfide

prasinezumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* SNCA (synucléine alpha, PARK1, PARK4, maladie de Parkinson (autosomique dominante, corps de Lewy) 4, synucléine-alpha, aSyn, composant non A4 du précurseur amyloïde, NACP)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), charnière (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfure avec la chaîne légère (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (225-225'':228-228'')-bisdisulfure

prasinezumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* SNCA (sinucleína alfa, PARK1, PARK4, enfermedad de Parkinson (autosómica dominante, cuerpos de Lewy) 4, sinucleína-alfa, aSyn, componente no A4 del precursor amieloide, NACP)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV3-7*01 (87.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120(213) (117-214), bisagra (215-229), CH2 (230-339), CH3 E12 (355), M14(357) (340-444), CHS (445-446)) (117-446)], (219-220')-disulfuro con la cadena ligera (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (81.20%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYGMSWVRQA PGKGLEWVAS  50
ISSGGGSTYY PDNVKGRFTI SRDDAKNSLY LQMNSLRAED TAVYYCARGG 100
AGIDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKSIQTLL YSSNQKNYLA WFQQKPGKAP  50
KLLIYWASIR KSGVPSRFSG SGSGTDFTLT ISSLQPEDLA TYYCQQYYSY 100
PLTFGGGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 143-199 260-320 366-424
22"-96" 143"-199" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-94' 140'-200'
23"'-94"' 140"'-200"'
Inter-H-L (h 5-CL 126) 219-220' 219"-220"'
Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

ralanitenum

ralaniten — (2*R*)-3-[4-(2-{4-[(2*S*)-3-chloro-2-hydroxypropoxy]phenyl}propan-2-yl)phenoxy]propane-1,2-diol

ralaniten — (2*R*)-3-[4-(2-{4-[(2*S*)-3-chloro-2-hydroxypropoxy]phényl}propan-2-yl)phénoxy]propane-1,2-diol

ralanitén — (2*R*)-3-[4-(2-{4-[(2*S*)-3-cloro-2-hidroxipropoxi]fenil}propan-2-il)fenoxi]propano-1,2-diol

$C_{21}H_{27}ClO_5$



ravulizumabum #

ravulizumab — immunoglobulin G2-4-kappa, anti-[*Homo sapiens* C5 (complement 5)], humanized monoclonal antibody; gamma2-4 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), hinge (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (238-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (238-448)], (146-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

ravulizumab

immunoglobuline G2-4-kappa, anti-[*Homo sapiens* C5 (complément 5)], anticorps monoclonal humanisé; chaîne lourde gamma2-4 (1-448) [VH humanisé (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), charnière (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224'':225-225'':228-228'':231-231'')-tétrakisdisulfure

ravulizumab

inmunoglobulina G2-4-kappa, anti-[*Homo sapiens* C5 (complemento 5)], anticuerpo monoclonal humanizado; cadena pesada gamma2-4 (1-448) [VH humanizado (*Homo sapiens* IGHV1-46*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*01 (CH1 (123-220), bis (221-232), CH2 1.6-1.1 (233-237)) (123-237) -*Homo sapiens* IGHG4*01 (CH2 1-125 (240-341), CH3 M107>L (429), N114>S (435) (342-446), CHS (447-448)) (240-448)], (146-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (84.20%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*0, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (224-224'':225-225'':228-228'':231-231'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGHIFS NYWIQWVRQA PGQGLEWMGE  50
ILPGSGHTEY TENFKDRVTM TRDTSTSTVY MELSSLRSED TAVYYCARYF 100
FGSSPNWYFD VWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSNFGT 200
QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVLH EALHSHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCGASENIY GALNWYQQKP GKAPKLLIYG  50
ATNLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQN VLNTPLTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 262-322 368-426
22''-96'' 149''-205'' 262''-322'' 368''-426''
Intra-L (C23-C104) 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L (CH1 10-CL 126) 136-214' 136''-214'''
Inter-H-H (h 4, h 5, h 8, h 11) 224-224'' 225-225'' 228-228'' 231-231''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

redasemtidum
redasemtide — human high mobility group protein B1 (HMG-1)-(1-44)-peptide (including Met[1]), chemically synthesized (without any modified residues)

rédasemtide — protéine B1 du groupe à haute mobilité humaine (HMGB1)-(1-44)- peptide (incluant Met[1]), synthétisé chimiquement (sans aucun résidu modifié)

redasemtida — proteína B1 del grupo de alta movilidad humana (HMGB1)-(1-44)-péptido (incluyendo Met[1]), sintetizado químicamente (sin restos modificados)

$C_{224}H_{351}N_{65}O_{64}S_3$

Sequence / Séquence / Secuencia
MGKGDPKKPR GKMSSYAFFV QTCREEHKKK HPDASVNFSE FSKK 44

relmapirazinum
relmapirazin — *N*,*N*'-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-serine

relmapirazine — *N*,*N*'-(3,6-diaminopyrazine-2,5-dicarbonyl)di-D-sérine

relmapirazina — *N*,*N*'-(3,6-diaminopirazina-2,5-dicarbonil)di-D-serina

$C_{12}H_{16}N_6O_8$



reloxaliasum #
reloxaliase — oxalate decarboxylase (OxdC, EC=4.1.1.2, *Bacillus subtilis* gene yvrK), hexamer, produced in *Escherichia coli*

réloxaliase — oxalate décarboxylase (OxdC, EC=4.1.1.2, gène yvrK de *Bacillus subtilis*), hexamère, produit par *Escherichia coli*

reloxaliasa — oxalate decarboxilasa (OxdC, EC=4.1.1.2, gén yvrK de *Bacillus subtilis*), hexámero, producido por *Escherichia coli*

$C_{1961}H_{2991}N_{519}O_{588}S_{10}$ (monomer)

Monomer sequence / Séquence du monomère / Secuencia del monómero
MKKQNDIPQF IRGDKGATVK IPRNIERDRQ NPDMLVPPET DHGTVSNMKF 50
SFSDTHNRLE KGGYAREVTV RELPISENLA SVNMRLKPGA IRELHWHKEA 100
EWAYMIYGSA RVTIVDEKGR SFIDDVGEGD LWYFPSGLPH SIQALEEGAE 150
FLLVFDDGSF SENSTFQLTD WLAHTPKEVI AANFGVTKEE ISNLPGKEKY 200
IFENQLPGSL KDDIVEGPNG EVPYPFTYRL LEQEPIESEG GKVYIADSTN 250
FKVSKTIASA LVTVEPGAMR ELHWHPNTHE WQYYISGKAR MTVFASDGHA 300
RTFNYQAGDV GYVPFAMGHY VENIGDEPLV FLEIFKDDHY ADVSLNQWLA 350
MLPETFVQAH LDLGKDFTDV LSKEKHPVVK KKCSK 385

remlarsenum

remlarsen

(2*RS*)-3-{[6-(cholest-5-en-3β-yloxy)hexyl]oxy}-2-hydroxypropyl hydrogen 2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-3'-adenylate duplex with *all-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-2'-deoxy-2'-fluorouridine

remlarsen

hydrogéno-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-3'-adénylate de (2*RS*)-3-{[6-(cholest-5-én-3β-yloxy)hexyl]oxy}-2-hydroxypropyle duplex avec *tout-P-ambo-P*-thiouridylyl-(5'→3')-*P*-thiouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-2'-désoxy-2'-fluorouridylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorocytidylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-2'-désoxy-2'-fluorouridine

remlarsén

hidrógeno-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanylyl-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-3'-adenilato de (2*RS*)-3-{[6-(colest-5-en-3β-iloxi)hexil]oxi}-2-hidroxipropilo dúplex con *todo-P-ambo-P*-tiouridilil-(5'→3')-*P*-tiouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-guanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-adenilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorocitidilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-2'-desoxi-2'-fluorouridina

$C_{504}H_{640}F_{12}N_{171}O_{326}P_{47}S_2$



rezafungini acetas
rezafungin acetate

N[5.1],6-anhydro[(4*R*,5*R*)-4-hydroxy-2-[3[4]-(pentyloxy)[1[1],2[1]:2[4],3[1]-terphenyl]-1[4]-carboxamido]-5-[2-(trimethylazaniumyl)ethyl]-L-ornithyl-L-threonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3*S*,4S)-3-hydroxy-4-methyl-L-proline] acetate

acétate de rézafungine

acétate de *N*[5.1],6-anhydro[(4*R*,5*R*)-4-hydroxy-2-[3[4]-(pentyloxy)[1[1],2[1]:2[4],3[1]-terphényl]-1[4]-carboxamido]-5-[2-(triméthylazaniumyl)éthyl]-L-ornithyl-L-thréonyl-*trans*-4-hydroxy-L-prolyl-(4*S*)-4-hydroxy-4-(4-hydroxyphényl)-L-thréonyl-L-thréonyl-(3*S*,4S)-3-hydroxy-4-méthyl-L-proline]

acetato de rezafungina

acetato de *N*[5.1],6-anhidro[(4*R*,5*R*)-4-hidroxi-2-[3[4]-(pentiloxi)[1[1],2[1]:2[4],3[1]-terfenil]-1[4]-carboxamido]-5-[2-(trimetilazaniumil)etil]-L-ornitil-L-treonil-*trans*-4-hidroxi-L-prolil-(4*S*)-4-hidroxi-4-(4-hidroxifenil)-L-treonil-L-treonil-(3*S*,4S)-3-hidroxi-4-metil-L-prolina]

$C_{63}H_{85}N_8O_{17} \cdot C_2H_3O_2$



riamilovirum
riamilovir

7-(methylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4(1*H*)-one

riamilovir — 7-(méthylsulfanyl)-3-nitro[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4(1*H*)-one

riamilovir — 7-(metilsulfanil)-3-nitro[1,2,4]triazolo[5,1-*c*][1,2,4]triazin-4(1*H*)-ona

$C_5H_4N_6O_3S$



rivoceranibum

rivoceranib — *N*-[4-(1-cyanocyclopentyl)phenyl]-2-{[(pyridin-4-yl)methyl]amino}pyridine-3-carboxamide

rivocéranib — *N*-[4-(1-cyanocyclopentyl)phényl]-2-{[(pyridin-4-yl)méthyl]amino}pyridine-3-carboxamide

rivoceranib — *N*-[4-(1-cianociclopentil)fenil]-2-{[(piridin-4-il)metil]amino}piridina-3-carboxamida

$C_{24}H_{23}N_5O$



rivogenlecleucelum #

rivogenlecleucel — Human culture expanded genetically modified allogenic T cells for cell-based therapy. Cells are derived from isolated blood of a healthy human donor chosen by available HLA match (haploidentical up to fully matched) and are transduced with a Gibbon ape leukemia virus (GalV) pseudotyped gammaretroviral vector carrying an inducible caspase 9 suicide transgene and a truncated CD19 marker gene allowing selection, and a drug binding domain consisting of human FK506 (tacrolimus)-binding protein (FKBP12) with an F36V mutation. Cells exhibit anti-infective activity as adjunctive T-cell therapy in combination with allogenic hematopoietic stem cell transplantation, in combination with an inducible suicide mechanism in the event of donor T-cell induced graft versus host disease (GvHD).

rivogenlecleucel — Lymphocytes T humains allogéniques, en culture d'expansion et modifiés génétiquement en vue d'une thérapie cellulaire. Les cellules sont dérivées du sang prélevé chez un donneur sain choisi pour sa compatibilité HLA (de haploidentique à correspondant totalement) et sont transduites avec un vecteur rétroviral gamma

	pseudotypé virus de la leucémie du singe Gibbon (GalV) transportant un transgène suicide inductible de la caspase 9 et un gène CD19 tronqué comme marqueur permettant la sélection, ainsi qu'un domaine de liaison médicamenteuse consistant en la protéine humaine (FKBP12) se liant au tacrolimus (FK506) avec une mutation F36V. Les cellules montrent une activité anti-infectieuse comme thérapie adjuvante de lymphocytes T en association avec la transplantation de cellules souches hématopoïétiques allogéniques, en association aussi avec un mécanisme suicide inductible en cas de réaction du greffon contre l'hôte (GVH) induit par les lymphocytes T du donneur.
rivogenlecleucel	Linfocitos T alogénicos, humanos, expandidos en cultivo y modificados genéticamente para terapia celular. Las células se derivan a partir de sangre aislada de un donante humano sano elegido por su compatibilidad HLA (desde haploidéntico hasta totalmente coincidente) y están transducidas con un vector gamma-retroviral seudotipado del virus de la leucemia de monos Gibbon (GalV) que porta un transgen inducible suicida de caspasa 9 y un gen CD19 truncado como marcador que permite la selección, y un dominio de unión a drogas consistente en la proteína de unión al tacrólimus (FK506) humana (FKBP12) con una mutación F36V. Las células muestran actividad anti-infecciosa en terapia adyuvante de linfocitos T en combinación con trasplante alogénico de células madre hematopoyéticas, en combinación con un mecanismo suicida inducible en caso de enfermedad injerto contra huésped (EICH) inducida por los linfocitos T del donante.
rovazolacum	
rovazolac	ethyl {5-[3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1*H*-pyrazol-1-yl}acetate
rovazolac	{5-[3'-(méthanesulfonyl)[1,1'-biphényl]-4-yl]-3-(trifluorométhyl)-1*H*-pyrazol-1-yl}acétate d'éthyle
rovazolac	{5-[3'-(metanosulfonil)[1,1'-bifenil]-4-il]-3-(trifluorometil)-1*H*-pirazol-1-il}acetato de etilo
	$C_{21}H_{19}F_3N_2O_4S$ 
seliforantum	
seliforant	6-[3-(methylamino)azetidin-1-yl]-2-(2-methylpropyl)pyrimidin-4-amine

séliforant	6-[3-(méthylamino)azétidin-1-yl]-2-(2-méthylpropyl)pyrimidin-4-amine
seliforant	6-[3-(metilamino)azetidin-1-il]-2-(2-metilpropil)pirimidin-4-amina

$C_{12}H_{21}N_5$



setrusumabum #

setrusumab	immunoglobulin G2-lambda, anti-[*Homo sapiens* SOST (sclerostin)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), hinge (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (219-219'':220-220'':223-223'':226-226'')-tetrakisdisulfide
sétrusumab	immunoglobuline G2-lambda, anti-[*Homo sapiens* SOST (sclérostine)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), charnière (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (219-219'':220-220'':223-223'':226-226'')-tétrakisdisulfure
setrusumab	inmunoglobulina G2-lambda, anti-[*Homo sapiens* SOST (esclerostina)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-443) [*Homo sapiens* VH (IGHV3-66*01 (89.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG2*01, G2m.. (CH1 (118-215), bisagra (216-227), CH2 V45.1 (278) (228-336), CH3 (337-441), CHS (442-443)) (118-443)], (131-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV2-23*02 (92.60%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (219-219'':220-220'':223-223'':226-226'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG LVQPGGSLRL SCAASGFTFR SHWLSWVRQA PGKGLEWVSN  50
INYDGSSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDT 100
YLHFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SNFGTQTYTC 200
NVDHKPSNTK VDKTVERKCC VECPPCPAPP VAGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTFRVVS 300
VLTVVHQDWL NGKEYKCKVS NKGLPAPIEK TISKTKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPMLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIALTQPASV SGSPGQSITI SCTGTSSDVG DINDVSWYQQ HPGKAPKLMI  50
YDVNNRPSGV SNRFSGSKSG NTASLTISGL QAEDEADYYC QSYAGSYLSE 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	257-317	363-421
	22"-96"	144"-200"	257"-317"	363"-421"
Intra-L (C23-C104)	22'-90'	139'-198'		
	22'"-90'"	139'"-198'"		
Inter-H-L (CH1 10-CL 126)	131-216'	131"-216'"		
Inter-H-H (h 4, h 5, h 8, h 11)	219-219"	220-220"	223-223"	226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

spartalizumabum #

spartalizumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;
gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimer (223-223'':226-226'')-bisdisulfide

spartalizumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dimère (223-223'':226-226'')-bisdisulfure

espartalizumab — inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;

cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens* IGHV1-69-2*01 (75.00%) -(IGHD) -IGHJ6*01) [8.8.10] (1-117) -*Homo sapiens* IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS K2>del (443)) (118-443)], (131-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV3D-11*03 (75.80%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (114'-220')]; dímero (223-223":226-226")-bisdisulfuro



Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLRI SCKGSGYTFT TYWMHWVRQA TGQGLEWMGN  50
IYPGTGGSNF DEKFKNRVTI TADKSTSTAY MELSSLRSED TAVYYCTRWT 100
TGTGAYWGQG TTVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLG         443
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCKSSQSLL DSGNQKNFLT WYQQKPGQAP  50
RLLIYWASTR ESGVPSRFSG SGSGTDFTFT ISSLEAEDAA TYYCQNDYSY 100
PYTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 258-318 364-422
22"-96" 144"-200" 258"-318" 364"-422"
Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"
Inter-H-L (h 5-CL 126) 131-220' 131"-220'"
Inter-H-H (h 11, h 14) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

sultimotidum alfa #
sultimotide alfa

a fusion protein consisting of fragments of hepatitis B virus transcription factor X, large S-protein antigen (envelope antigen), B antigen (core antigen) and of a C-terminal six-histidine tag, expressed by engineered whole heat-killed *Saccharomyces cerevisiae*, glycoform alfa;

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-{des-(69-83)-[P^{59}>F]pro-tein X (hepatitis B virus)-(52-127)-peptide (9-69)}-{[M^{1}>E,G^{3}>Q,Q^{10}>K,P^{19}S,G^{35}>R,N^{39}>A,H^{51}>T,P^{65}>L,T^{86}>Q,A^{91}>N]large S protein (hepatitis B virus) (70-243)}-{[T^{4}>I,V^{25}>I,N^{207}>S,L^{209}>V,L^{213}>I]small S protein (hepatitis B virus) (244-469)}-{des-Met^{1}-[S^{12}>T]capsid protein (hepatitis B virus) (470-651)}-His_{6} (652-657) fusion protein, produced in *Saccharomyces cerevisiae,* glycoform alfa

sultimotide alfa

protéine de fusion consistant en des fragments du facteur X de transcription du virus de l'hépatite B, de l'antigène de la grande protéine S (antigène de l'enveloppe), antigène B (antigène core) et d'un fragment de 6 histidines, produite par une souche de *Saccharomyces cerevisiae* inactivée par la chaleur, glycoforme alfa:

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-{dès-(69-83)-[P^{59}>F]pro-téine X (virus de l'hépatite B)-(52-127)-peptide (9-69)}-{[M^{1}>E,G^{3}>Q,Q^{10}>K,P^{19}S,G^{35}>R,N^{39}>A,H^{51}>T,P^{65}>L,T^{86}>Q,A^{91}>N]grande protéine S (virus de l'hépatite B) (70-243)}-{[T^{4}>I,V^{25}>I,N^{207}>S,L^{209}>V,L^{213}>I]petite protéine S (virus de l'hépatite B) (244-469)}-{dès-Mét^{1}-[S^{12}>T]protéine de la capside (virus de l'hépatite B) (470-651)}-His_6 (652-657) protéine de fusion, produite par *Saccharomyces cerevisiae,* glycoforme alfa

sultimotida alfa

proteína de fusión consistente en los fragmentos del factor X de transcripción del virus de la hepatitis B, del antígeno de la proteína S grande (antígeno de la envoltura), antígeno B (antígeno nuclear) y de un fragmento de 6 histidinas, producida por una cepa de *Saccharomyces cerevisiae* inactivada por el calor, glicoforma alfa:

Met-Ala-Asp-Glu-Ala-Pro-Thr-Ser-{des-(69-83)-[P^{59}>F]proteína X (virus de la hepatitis B)-(52-127)-péptido}-{[M^{1}>E,G^{3}>Q,Q^{10}>K,P^{19}S,G^{35}>R,N^{39}>A,H^{51}>T,P^{65}>L,T^{86}>Q,A^{91}>N]proteína S grande (virus de la hepatitis B)}-{[T^{4}>I,V^{25}>I,N^{207}>S,L^{209}>V,L^{213}>I]proteína S pequeña (virus de la hepatitis B)}-{des-Met^{1}-[S^{12}>T]proteína de la cápside (virus de la hepatitis B)}-His_6 proteína de fusión, producida por *Saccharomyces cerevisiae,* glicoforma alfa

Sequence / Séquence / Secuencia

```
MADEAPTSHL SLRGLFVCAF SSAGPNAHQF LPKVLHKRTL GLSAMSTTDL 50
EAYFKDCLFK DWEELGEELE GQWSSKPRKG MGTNLSVSNP LGFFPDHQLD 100
PAFRANSANP DWDFNPNKDT WPEANQVGVG AFGLGFTPPH GGLLGWSPQA 150
QGILQTVPAN PPPASTNRQS GRQPTPISPP LRDSHPQAMQ WNSTTFHQAL 200
LDPRVRGLYF PAGGSSSGTV NPVPTTASPI SSIFSRTGDP ALNMENITSG 250
FLGPLLVLQA GFFLLTRILT IPQSLDSWWT SLNFLGGTTT CPGQNSQSPT 300
SNHSPTSCPP ICPGYRWMCL RRFIIFLFIL LLCLIFLLVL LDYQGMLPVC 350
PLLPGTSTTS TGPCKTCTIP AQGTSMFPSC CCTKPSDGNC TCIPIPSSWA 400
FARFLWEWAS VRFSWLSLLV PFVQWFVGLS PTVWLSVIWM MWYWGPSLYS 450
IVSPFIPLLP IFFCLWVYID IDPYKEFGAT VELLSFLPSD FFPSVRDLLD 500
TASALYREAL ESPEHCSPHH TALRQAILCW GELMNLATWV GSNLEDPASR 550
ELVVSYVNVN MGLKIRQLLW FHISCLTFGR ETVLEYLVSF GVWIRTPPAY 600
RPPNAPILST LPETTVVRRR GRSPRRRTPS PRRRRSQSPR RRRSQSRESQ 650
CHHHHHH                                               657
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
18-350 57-308 291-319 312-529 333-380
364-367 381-390 382-392 464-651 516-575

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-84 Asn-192 Asn-246 Asn-302 Asn-389

tabelecleucelum
tabelecleucel

Human culture enriched allogenic Epstein-Barr virus-specific cytotoxic T cells (EBV-CTL) for cell-based therapy. Cells are isolated from blood of EBV seropositive healthy human donors. EBV-CTLs exhibit human leukocyte antigen (HLA)-restricted cytotoxic activity against EBV+ cells in allogeneic hematopoietic cell transplant patients with EBV associated post-transplant lymphoproliferative disease.

tabélecleucel	Lymphocytes T cytotoxiques spécifiques du virus d'Epstein-Barr (EBV-CTL), allogéniques, humains, enrichis en culture pour thérapie cellulaire. Les cellules sont isolées à partir du sang de donneurs humains sains séropositifs à l'EBV. Les EBV-CTL montrent une activité cytotoxique restreinte à l'antigène leucocytaire humain (HLA) contre les cellules EBV+ chez des patients transplantés avec des cellules hématopoïétiques allogéniques souffrants d'un syndrome lymphoprolifératif associé à l'EBV post-transplantation.
tabelecleucel	Linfocitos T citotóxicos específicos del virus de Epstein-Barr (EBV-CTL), alogénicos, humanos, enriquecidos en cultivo para terapia celular. Las células están asiladas a partir de sangre de donantes humanos sanos seropositivo para EBV. Los EBV-CTLs muestran actividad citotóxica restringida por HLA contra células EBV+ in pacientes trasplantados con células hematopoyéticas alogénicas con enfermedad linfoproliferativa post-trasplante asociada a EBV.
talacotuzumabum #	
talacotuzumab	immunoglobulin G1-2-kappa, anti-[*Homo sapiens* IL3RA (interleukin 3 receptor subunit alpha, interleukin 3 receptor alpha (low affinity), CD123)], humanized monoclonal antibody; gamma1-2 heavy chain (1-450) [humanized VH (*Homo sapiens* IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -hinge (219-233) -CH2 1.6-1.1 (234-239)) (121-239) -*Homo sapiens* IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (229-229'':232-232'')-bisdisulfide
talacotuzumab	immunoglobuline G1-2-kappa, anti-[*Homo sapiens* IL3RA (sous-unité alpha du récepteur de l'interleukine 3, récepteur alpha (faible affinité) de l'interleukine 3, CD123)], anticorps monoclonal humanisé; chaîne lourde gamma1-2 (1-450) [VH humanisé (*Homo sapiens* IGHV5-51*01 (82.70%) -(IGHD) -IGHJ3*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -charnière (219-233) -CH2 1.6-1.1 (234-239))(121-239) -*Homo sapiens* IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1, V101 (114'-220')]; dimère (229-229'':232-232'')-bisdisulfure

talacotuzumab

inmunoglobulina G1-2-kappa, anti-[*Homo sapiens* IL3RA (subunidad alfa del receptor de la interleukina 3, receptor alfa (baja afinidad) de la interleukina 3, CD123)], anticuerpo monoclonal humanizado;
cadena pesada gamma1-2 (1-450) [VH humanizado (*Homo sapiens* IGHV5-51*01 (82.70%) -(IGHD) - IGHJ3*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01 (CH1 G1m17, K120 (217) (121-218) -bisagra (219-233) - CH2 1.6-1.1 (234-239)) (121-239) -*Homo sapiens* IGHG2*01 (CH2 1-125, S3>D (242), G2m.. V45.1 (285), G110>A (330), I117>E (335) (240-343) -CH3 nG1m1 E12 (359), M14 (361) (344-448), CHS (449-450)) (240-450)], (223-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (90.10%) -IGKJ2*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1, V101 (114'-220')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCKGSGYSFT DYYMKWARQM PGKGLEWMGD  50
IIPSNGATFY NQKFKGQVTI SADKSISTTY LQWSSLKASD TAMYYCARSH 100
LLRASWFAYW GQGTMVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PDVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STFRVVSVLT VVHQDWLNGK EYKCKVSNKA LPAPEEKTIS KTKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCESSQSLL NSGNQKNYLT WYQQKPGQPP  50
KPLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYSY 100
PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 147-203 264-324 370-428
22"-96" 147"-203" 264"-324" 370"-428"
Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"
Inter-H-L (h 5-CL 126) 223-220' 223"-220'"
Inter-H-H (h 11, h 14) 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

tasadenoturevum #
tasadenoturev

Conditionally replicating adenovirus (CRAd) serotype 5 carrying a 24-bp deletion in early E1A gene and insertion of an integrin-binding motif (Arg-Gly-Asp) (RGD) motif into the H1 loop of the fiber knob.

tasadénoturev

adénovirus de sérotype 5 dont la réplication est conditionnelle et portant une délétion de 24 paires de bases sur le gène précoce E1A et l'insertion d'un motif d'union à l'intégrine dans la boucle H1 du *knob* de la fibre

tasadenoturev — Adenovirus de serotipo 5, con replicación condicionada, portando una deleción de 24 pares de bases en el gen temprano E1A y la inserción de un motivo de unión a integrina (Arg-Gly-Asp) (RGD) en el bucle H1 del *knob* de fibra

tasipimidinum

tasipimidine — *rac*-2-[(1*R*)-5-methoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidine — *rac*-2-[(1*R*)-5-méthoxy-3,4-dihydro-1*H*-2-benzopyran-1-yl]-4,5-dihydro-1*H*-imidazole

tasipimidina — *rac*-2-[(1*R*)-5-metoxi-3,4-dihidro-1*H*-2-benzopiran-1-il]-4,5-dihidro-1*H*-imidazol

$C_{13}H_{16}N_2O_2$



telacebecum

telacebec — 6-chloro-2-ethyl-*N*-[(4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}phenyl)methyl]imidazo[1,2-*a*]pyridine-3-carboxamide

télacébec — 6-chloro-2-éthyl-*N*-[(4-{4-[4-(trifluorométhoxy)phényl]pipéridin-1-yl}phényl)méthyl]imidazo[1,2-*a*]pyridine-3-carboxamide

telacebec — 6-cloro-2-etil-*N*-[(4-{4-[4-(trifluorometoxi)fenil]piperidin-1-il}fenil)metil]imidazo[1,2-*a*]piridina-3-carboxamida

$C_{29}H_{28}ClF_3N_4O_2$



temavirsenum

temavirsen — [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all*-*P*-*ambo*-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl

	-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-ethane-1,1-diyl]cytidylyl-(3'→5')-2'-deoxy-3'-adenylate
témavirsen	hydrogéno-*tout-P-ambo*-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thiouridylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-éthane-1,1-diyl]cytidylyl-(3'→5')-2'-désoxy-3'-adénylate de [(2*S*,4*R*)-1-{1-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acétamido-2-désoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]méthyle
temavirsén	hydrógeno-*todo-P-ambo*-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metil-*P*-tiouridilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tiouridill-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diyl]-*P*-thiocytidylyl-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]-*P*-tiocitidilil-(3'→5')-2'-*O*,4'-*C*-[(1*S*)-etano-1,1-diil]citidilil-(3'→5')-2'-desoxi-3'-adenilato de [(2*S*,4*R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-[(3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino]-3-oxopropoxi}metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oil}-4-hidroxipirrolidin-2-il]metilo

$C_{295}H_{429}N_{78}O_{146}P_{19}S_{17}$

(3'-5')Amoe=m^{5}Cmoe=Amoe=m^{5}Cmoe=m^{5}Cmoe=Amoe=m^{5}Umoe=
=dT=dG=U=C=dA=C=dA=C=dT=C=C-dA-(R1)



dX : 2'-deoxy-X / dX : 2'-désoxy-X / dX: 2'-desoxi-X
Xmoe : 2'-*O*-(2-methoxyethyl)-X / Xmoe: 2'-*O*-(2-méthoxyéthyl)-X /
Xmoe : 2'-*O*-(2-metoxietil)-X



tibulizumabum #

tibulizumab	immunoglobulin G4-kappa anti-[*Homo sapiens* TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257)] , each heavy chain being fused to a scFv anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody, bispecific tetravalent; gamma4 heavy chain anti-TNFSF13B fused to a scFv anti-IL17A (1-714) [gamma4 heavy chain {(*Homo sapiens* VH (IGHV4-34*01 (100.00%) -(IGHD) -IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), hinge S10>P (231) (222-233), CH2 (234-343), CH3L125>del (344-447), CHS G1>del, K2>del) (124-447)} (1-447) -16-mer linker (448-463) -scFv {(humanized VH (*Homo sapiens* IGHV1-69*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglycyl-seryl) linker (583-602) -humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714)} (464-714)], (137-214')-disulfide with kappa light chain anti-TNFSF13B (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide
tibulizumab	immunoglobuline G4-kappa anti-[*Homo sapiens* TNFSF13B (membre 13B de la superfamille des facteurs de nécrose tumorale (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, facteur d'activation des lymphocytes B, activateur des lymphocytes B, CD257)], chaque chaîne lourde étant fusionnée à un scFv anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé, bispécifique tétravalent;

	chaîne lourde gamma4 anti-TNFSF13B fusionnée à un scFv anti-IL17A (1-714) [chaîne lourde gamma4 {(*Homo sapiens* VH (IGHV4-34*01 (100.00%) -(IGHD) -IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), charnière S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447)} (1-447) -16-mer linker (448-463) -scFv {(VH humanisé (*Homo sapiens* IGHV1-69*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tétra(tétraglycyl-séryl) linker (583-602) -V-KAPPA humanisé (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714)} (464-714)], (137-214')-disulfure avec la chaîne légère anti-TNFSF13B (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure
tibulizumab	inmunoglobulina G4-kappa anti-[*Homo sapiens* TNFSF13B (miembro 13B de la superfamilia de los factores de necrosis tumoral (TNF), BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, factor de activación de linfocitos B, activador de linfocitos B, CD257)], cada cadena pesada estando fusionada con un scFv anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado, biespecífico tetravalente; cadena pesada gamma4 anti-TNFSF13B fusionada con un scFv anti-IL17A (1-714) [cadena pesada gamma4 {(*Homo sapiens* VH (IGHV4-34*01 (100.00%) -(IGHD) -IGHJ4*01) [8.7.17] (1-123) -*Homo sapiens* IGHG4*01 (CH1 (124-221), bisagra S10>P (231) (222-233), CH2 (234-343), CH3 L125>del (344-447), CHS G1>del, K2>del) (124-447)} (1-447) -16-mer de conexión (448-463) -scFv {(VH humanizado (*Homo sapiens* IGHV1-69*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.12] (464-582) -20-mer tetra(tetraglicil-seril) linker (583-602) -V-KAPPA humanizado (*Homo sapiens* IGKV2D-29*02 (89.00%) -IGKJ2*02) [11.3.9] (603-714)} (464-714)], (137-214')-disulfuro con la cadena ligera anti-TNFSF13B (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*05, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQP PGKGLEWIGE  50
INHSGSTNYN PSLKSRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARGYY 100
DILTGYYYYF DYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEFLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350
VYTLPPSQEE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSPGG 450
GGSGGGGTGG GGSQVQLVQS GAEVKKPGSS VKVSCKASGY KFTDYHIHWV 500
RQAPGQCLEW MGVINPTYGT TDYNQRFKGR VTITADESTS TAYMELSSLR 550
SEDTAVYYCA RYDYFTGTGV YWGQGTLVTV SSGGGGSGGG GSGGGGSGGG 600
GSDIVMTQTP LSLSVTPGQP ASISCRSSRS LVHSRGETYL HWYLQKPGQS 650
PQLLIYKVSN RFIGVPDRFS GSGSGTDFTL KISRVEAEDV GVYYCSQSTH 700
LPFTFGCGTK LEIK                                        714
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS RYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD STLTISSLEP EDFAVYYCQQ RSNWPRTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSNTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104, except for *) 22-95 150-206 264-324 370-428
485-559 507-707 * 625-695
22"-95" 150"-206" 264"-334" 370"-428"
485"-559" 507"-707" * 625"-695"

Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"

Inter-H-L (CH1 10-CL 126) 137-214' 137"-214'"

Inter-H-H (h 8, h 11) 229-229" 232-232"

*Disulfide bridge between the scFv VHC49 (507, 507") and V-KAPPA C120 (707, 707")

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tigilanoli tiglas

tigilanol tiglate

(1a*R*,1b*R*,1c*S*,2a*R*,3*S*,3a*S*,6a*S*,6b*R*,7*R*,8*R*,8a*S*)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-4-oxo-1,1a,1b,1c,2a,3,3a,4,6a,6b,7,8-dodecahydro-8a*H*-cyclopropa[5',6']benzo[1',2':-7,8]azuleno[5,6-*b*]oxirene-8,8a-diyl 8a-[(2*S*)-2-methylbutanoate] 8-[(2*E*)-2-methylbut-2-enoate]

tiglate de tigilanol

8a-[(2*S*)-2-méthylbutanoate] et 8-[(2*E*)-2-méthylbut-2-énoate] de (1a*R*,1b*R*,1c*S*,2a*R*,3*S*,3a*S*,6a*S*,6b*R*,7*R*,8*R*,8a*S*)-3,3a,6b-trihydroxy-2a-(hydroxyméthyl)-1,1,5,7-tétraméthyl-4-oxo-1,1a,1b,1c,2a,3,3a,4,6a,6b,7,8-dodécahydro-8a*H*-cyclopropa[5',6']benzo[1',2':7,8]azuléno[5,6-*b*]oxirène-8,8a-diyle

toglato de tigilanol

8a-[(2*S*)-2-metilbutanoato] y 8-[(2*E*)-2-metilbut-2-enoato] de (1a*R*,1b*R*,1c*S*,2a*R*,3*S*,3a*S*,6a*S*,6b*R*,7*R*,8*R*,8a*S*)-3,3a,6b-trihidroxi-2a-(hidroximetil)-1,1,5,7-tetrametil-4-oxo-1,1a,1b,1c,2a,3,3a,4,6a,6b,7,8-dodecahidro-8a*H*-ciclopropa[5',6']benzo[1',2':7,8]azuleno[5,6-*b*]oxireno-8,8a-diilo

$C_{30}H_{42}O_{10}$



tigolanerum

tigolaner

2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-methyl-5'-(pentafluoroethyl)-4'-(trifluoromethyl)-2'*H*-[1,3'-bipyrazol]-4-yl]benzamide

tigolaner

2-chloro-*N*-(1-cyanocyclopropyl)-5-[2'-méthyl-5'-(pentafluoroéthyl)-4'-(trifluorométhyl)-2'*H*-[1,3'-bipyrazol]-4-yl]benzamide

tigolaner

2-cloro-*N*-(1-cianociclopropil)-5-[2'-metil-5'-(pentafluoroetil)-4'-(trifluorometil)-2'*H*-[1,3'-bipirazol]-4-il]benzamida

$C_{21}H_{13}ClF_8N_6O$



tilsotolimodum

tilsotolimod

O,*O*'-(2-hydroxypropane-1,3-diyl) bis(hydrogen *all-P-ambo-P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-7-carba-*P*-thio-3'-guanylate)

tilsotolimod

bis(hydrogéno-*tout-P-ambo-P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-7-carba-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-7-carba-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-7-carba-*P*-thio-3'-guanylate) de *O*,*O*'-(2-hydroxypropane-1,3-diyle)

tilsotolimod

bis(hidrógeno-*todo-P-ambo-P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-7-carba-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-7-carba-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-7-carba-*P*-tio-3'-guanilato) de *O*,*O*'-(2-hidroxipropano-1,3-diilo)

$C_{223}H_{284}N_{74}O_{115}P_{22}S_{22}$





timrepigenum emparvovecum #

timrepigene emparvovec

Non-replicating recombinant adeno-associated virus serotype 2 (rAAV2) vector encoding the cDNA of human Rab escort protein 1 (CHM, REP-1), driven by the hybrid cytomegalovirus (CMV) enhancer/chicken beta-actin promoter (CBA).

timrépigène emparvovec

Vecteur viral adéno-associé recombinant de sérotype 2 (rAAV2) non-répliquant codant pour l'ADN cyclique (ADNc) de la protéine escorte Rab 1 (CHM, REP-1) humaine sous

	le contrôle de l'hybride de l'activateur du cytomégalovirus (CMV) et du promoteur de l'actine bêta du poulet (ABP, CBA).
timrepigén emparvovec	Vector no replicativo del Virus Adeno-asociado de serotipo 2 (rAAV2) que codifica el cDNA de la proteína escolta Rab 1 (CHM, REP-1) humana, impulsado por el híbrido del *enhancer* de citomegalovirus (CMV) y el promotor de la beta-actina de pollo (CBA).
tiragolumabum #	
tiragolumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* TIGIT (T-cell immunoreceptor with Ig domain and ITIM, V-set Ig member 9, VSIG9, V-set and transmembrane member 3, VSTM3)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), hinge (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfide with kappa light chain (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (235-235'':238-238'')-bisdisulfide
tiragolumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* TIGIT (immunorécepteur des lymphocytes T avec domaine Ig et ITIM, membre 9 de l'Ig V-set, VSIG9, membre 3 de l'Ig V-set et région transmembrane, VSTM3)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), charnière (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfure avec la chaîne légère (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (235-235'':238-238'')-bisdisulfure
tiragolumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* TIGIT (inmunoreceptor de linfocitos T con dominio Ig e ITIM, miembro 9 de la Ig V-set, VSIG9, miembro 3 de la Ig V-set y región transmembrana, VSTM3)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV6-1*01 (93.10%) -(IGHD) -IGHJ4*01) [10.9.16] (1-126) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K (223) (127-224), bisagra (225-239), CH2 (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-220')-disulfuro con la cadena ligera (1'-220') [*Homo sapiens* V-KAPPA (IGKV4-1*01 (97.00%) -IGKJ3*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dímero (235-235'':238-238'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQSGPG LVKPSQTLSL TCAISGDSVS SNSAAWNWIR QSPSRGLEWL  50
GKTYYRFKWY SDYAVSVKGR ITINPDTSKN QFSLQLNSVT PEDTAVFYCT 100
RESTTYDLLA GPFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK                                                  456
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSQTVL YSSNNKKYLA WYQQKPGQPP 50
NLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYST 100
PFTFGPGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-99 153-209 270-330 376-434
22"-99" 153"-209" 270"-330" 376"-434"

Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"

Inter-H-L (h 5-CL 126) 229-220' 229"-220'"

Inter-H-H (h 11, h 14) 235-235" 238-238"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

tirvalimogenum teraplasmidum #

tirvalimogene teraplasmid

plasmid DNA vector encoding E6 and E7 antigens of human papillomavirus types 16 and 18 (HPV 16/18), the extracellular domain of fms-like tyrosine kinase-3 ligand (FLT3L) and signal sequences of tissue plasminogen activator (tpa) driven by a cytomegalovirus promoter.

tirvalimogène téraplasmide

vecteur constitué d'ADN plasmidique codant pour les antigènes E6 et E7 des papillomavirus humains de types 16 et 18 (VPH 16/18), le domaine extracellulaire du ligand de la tyrosine kinase 3 semblable au *fms* (FLT3L) et les séquences signal de l'activateur tissulaire du plasmogène (tpa) sous le contrôle d'un promoteur de cytomégalovirus.

tirvalimogén teraplásmido

Vector de DNA plasmídico que codifica los antígenos E6 y E7 de los tipos 16 y 18 del virus del papiloma humano (VPH 16/18), el dominio extracelular del ligando de la tirosina quinasa-3 similar a *fms* (FLT3L) y secuencias señal del activador de plasminógeno tisular (tpa) impulsado por un promotor de citomegalovirus.

tisagenlecleucelum #

tisagenlecleucel

human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative lentiviral vector encoding an FMC63 anti-CD19 single chain variable fragment (scFv) 4-1BB/CD3zeta chimeric antigen receptor (CAR) under the control of the EF-1 alpha promoter. Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.

tisagenlecleucel	Lymphocytes T autologues humains en culture d'expansion, modifiés génétiquement en vue d'une thérapie génique avec cellules. Les cellules sont isolées à partir du sang prélevé chez le patient et sont transduites avec un veceur lentiviral non-répliquant codant pour le récepteur de l'antigène chimérique (CAR) FMC63 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) 4-1BB/CD3zêta (SFG-1928z CAR) sous le contrôle du promoteur EF-1 alpha. Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.
tisagenlecleucel	Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector lentiviral no replicativo que codifica para el receptor de antígenos quimérico (CAR) FMC63 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) 4-1BB/CD3zeta bajo el control del promotor EF-1 alfa. Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.

tislelizumabum #

tislelizumab	immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody; gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), hinge S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide
tislélizumab	immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens* IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), charnière S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure

tislelizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV4-59*01 (88.70%) -(IGHD) -IGHJ3*01 M123>T (113)) [8.7.12] (1-118) -*Homo sapiens* IGHG4*01 (CH1 (119-216), bisagra S10>P (226) (217-228), CH2 E1.4>P (231), F1.3>V (232), L1.2>A (233), D27>A (263) (229-338), CH3 R88>K (407) (339-443), CHS (444-445)) (119-445)], (132-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (81.20%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')];
dímero (224-224":227-227")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGFSLT SYGVHWIRQP PGKGLEWIGV  50
IYADGSTNYN PSLKSRVTIS KDTSKNQVSL KLSSVTAADT AVYYCARAYG 100
NYWYIDVWGQ GTTVTVSSAS TKGPSVFPLA PCSRSTSEST AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTKTYT 200
CNVDHKPSNT KVDKRVESKY GPPCPPCPAP PVAGGPSVFL FPPKPKDTLM 250
ISRTPEVTCV VVAVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 300
VSVLTVVHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 350
PSQEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFLYSKLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK       445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSESVS NDVAWYQQKP GQPPKLLINY  50
AFHRFTGVPD RFSGSGYGTD FTLTISSLQA EDVAVYYCHQ AYSSPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	145-201	259-319	365-423
	22"-95"	145"-201"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L (CH1 10-CL 126)	132-214'	132"-214'"		
Inter-H-H (h 8, h 11)	224-224"	227-227"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4;
295, 295"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

tralesinidasum alfa #
tralesinidase alfa

human α-*N*-acetylglucosaminidase fused to truncated human insulin-like growth factor II (IGF2) via a peptide linker, produced in Chinese hamster ovary (CHO) cells, glycoform alfa;

human α-*N*-acetylglucosaminidase (NAG, EC=3.2.1.50) (1-720) fusion protein with glycyl-L-alanyl-L-prolyltriglycyl-L-seryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-threonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-serylglycyl-L-alanyl-L-prolyl-[37-L-alanine(R^{37}>$A_{(781)}$)]human insulin-like growth factor II (somatomedin-A, T3M-11-derived growth factor, IGF-II) (8-67)-peptide (752-811), produced in Chinese hamster ovary (CHO) cells, glycoform alfa

tralésinidase alfa

alpha-*N*-acétylglucosaminidase humaine fusionnée au facteur II de croissance humain analogue à l'insuline (IGF2) tronqué, via un peptide de liaison, produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa;

alpha-*N*-acétylglucosaminidase humaine (NAG, EC=3.2.1.50) (1-720) protéine de fusion avec glycyl-L-alanyl-L-prolyltriglycyl-L-séryl-bis(L-prolyl-L-alanyl-L-prolyl-L-alanyl-L-prolyl-L-thréonyl)-bis(L-prolyl-L-alanyl)-triglycyl-L-prolyl-L-sérylglycyl-L-alanyl-L-prolyl-[37-L-alanine(R^{37}>$A_{(781)}$)]facteur II de croissance analogue à l'insuline humain (somatomédine-A, T3M-11-facteur de croissance dérivé, IGF-II) (8-67)-peptide (752-811), produit dans des cellules ovariennes de hamster chinois (CHO), glycoforme alfa

tralesinidasa alfa

alfa-*N*-acetilglucosaminidasa humana fusionada con el factor II de crecimiento humano análogo a la insulina (IGF2) truncada, vía un péptido de unión, producida en las células ováricas de hamster chino (CHO), glicoforma alfa;

alfa-*N*-acetilglucosaminidasa humana (NAG, EC=3.2.1.50) (1-720) proteína de fusión con glicil-L-alanil-L-proliltriglicil-L-seril-bis(L-prolil-L-alanil-L-prolil-L-alanil-L-prolil-L-treonil-bis(L-prolil-L-alanil)-triglicil-L-prolil-L-serilglicil-L-alanil-L-prolil-[37-L-alanina(R^{37}>$A_{(781)}$)]factor II de crecimiento análogo a la insulina humano (somatomedina-A, T3M-11-factor de crecimiento derivado, IGF-II) (8-67)-péptido (752-811), producido en las células ováricas de hamster chino (CHO), glicoforma alfa

Sequence / Séquence / Secuencia

```
DEAREAAAVR ALVARLLGPG PAADFSVSVE RALAAKPGLD TYSLGGGSAA 50
RVRVRGSTGV AAAAGLHRYL RDFCGCHVAW SGSQLRLPRP LPAVPGELTE 100
ATPNRYRYYQ NVCTQSYSFV WWDWARWERE IDWMALNGIN LALAWSGQEA 150
IWQRVYLALG LTQAEINEFF TGPAFLAWGR MGNLHTWDGP LPPSWHIKQL 200
YLQHRVLDQM RSFGMTPVLP AFAGHVPEAV TRVFPQVNVT KMGSWGHFNC 250
SYSCSFLLAP EDPIFPIIGS LFLRELIKEF GTDHIYGADT FNEMQPPSSE 300
PSYLAAATTA VYEAMTAVDT EAVWLLQGWL FQHQPQFWGP AQIRAVLGAV 350
PRGRLLVLDL FAESQPVYTR TASFQGQPFI WCMLHNFGGN HGLFGALEAV 400
NGGPEAARLF PNSTMVGTGM APEGISQNEV VYSLMAELGW RKDPVPDLAA 450
WVTSFAARRY GVSHPDAGAA WRLLLRSVYN CSGEACRGHN RSPLVRRPSL 500
QMNTSIWYNR SDVFEAWRLL LTSAPSLATS PAFRYDLLDL TRQAVQELVS 550
LYYEEARSAY LSKELASLLR AGGVLAYELL PALDEVLASD SRFLLGSWLE 600
QARAAAVSEA EADFYEQNSR YQLTLWGPEG NILDYANKQL AGLVANYYTP 650
RWRLFLEALV DSVAQGIPFQ QHQFDKNVFQ LEQAFVLSKQ RYPSQPRGDT 700
VDLAKKIFLK YYPRWVAGSW GAPGGGSPAP APTPAPAPTP APAGGGPSGA 750
PLCGGELVDT LQFVCGDRGF YFSRPASRVS ARSRGIVEEC CFRSCDLALL 800
ETYCATPAKS E                                         811
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
74-76 250-254 481-486 753-791 765-804 790-795

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-238 Asn-249 Asn-412 Asn-480 Asn-490 Asn-503 Asn-509

Glycosylation sites (O) / Sites de glycosylation (O) / Posiciones de glicosilación (O)
Ser-727 Thr-733 Thr-739 Ser-748

trilaciclibum

trilaciclib

2'-{[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino}-7',8'-dihydro-6'*H*-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-one

trilaciclib	2'-{[5-(4-méthylpipérazin-1-yl)pyridin-2-yl]amino}-7',8'-dihydro-6'*H*-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-*d*]pyrimidin]-6'-one
trilaciclib	2'-{[5-(4-metilpiperazin-1-il)piridin-2-il]amino}-7',8'-dihidro-6'*H*-spiro[ciclohexano-1,9'-pirazino[1',2':1,5]pirrolo[2,3-*d*]pirimidin]-6'-ona

$C_{24}H_{30}N_8O$



vactosertibum

vactosertib	2-fluoro-*N*-{[4-(6-methylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]methyl}aniline
vactosertib	2-fluoro-*N*-{[4-(6-méthylpyridin-2-yl)-5-([1,2,4]triazolo[1,5-*a*]pyridin-6-yl)-1*H*-imidazol-2-yl]méthyl}aniline
vactosertib	2-fluoro-*N*-{[4-(6-metilpiridin-2-il)-5-([1,2,4]triazolo[1,5-*a*]piridin-6-il)-1*H*-imidazol-2-il]metil}anilina

$C_{22}H_{18}FN_7$



vadacabtagenum leraleucelum #

vadacabtagene leraleucel	human culture expanded genetically modified autologous T cells for cell-based gene therapy. Cells are derived from isolated blood of the patient and are transduced with non-replicative retroviral vector encoding the SJ25C1 anti-CD19 single chain variable fragment (scFv) CD28/CD3zeta chimeric antigen receptor (SFG-1928z CAR). Cells exhibit anti-tumoral activity in patients with CD19-expressing B cell malignancies.
vadacabtagène léraleucel	Lymphocytes T humains autologues en culture d'expansion et modifiés génétiquement pour thérapie génique avec cellules. Les cellules sont dérivées du sang prélevé chez le patient et sont transduites avec un vecteur rétroviral non-répliquant codant pour le récepteur de

l'antigène chimérique SJ25C1 anti-CD-19 fragment de la chaîne simple de la région variable de l'anticorps (scFv) CD28/CD3zêta (SFG-1928z CAR). Les cellules montrent une activité anti-tumorale chez les patients présentant des lymphocytes B malins exprimant le CD19.

vadacabtagén leraleucel

Linfocitos T autólogos, humanos, expandidos en cultivo y modificados genéticamente, para terapia génica con células. Las células se derivan a partir de sangre aislada del paciente y están transducidas con un vector retroviral no replicativo que codifica para el receptor de antígenos quimérico SJ25C1 anti-CD19 fragmento de cadena simple de la región variable del anticuerpo (scFv) CD28/CD3zeta (SFG-1928z CAR). Las células muestran actividad anti-tumoral en pacientes con malignidades de linfocitos B que expresan CD19.

valzifloceptum #

valziflocept

human immunoglobulin gamma Fc region receptor II-b (FcγRII-b), extracellular N-terminal fragment, produced in *Escherichia coli*;

human low affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigen CD32)-(4-179) peptide (N-terminal extracellular portion), produced in *Escherichia coli*

valziflocept

récepteur II-b de la région Fc de l'immunoglobuline gamma humaine (FcγRII-b), fragment extracellulaire N-terminal, produit par *Escherichia coli;*

récepteur II-b de faible affinité pour la région Fc de l'immunoglobuline gamma humaine (IgG Fc récepteur II-b, CDw32, Fc-gamma RII-b, FcRII-b, antigène CD32)-(4-179) peptide (partie extracellulaire

valziflocept

receptor II-b de la región Fc de la inmunoglobulina gamma humana (FcγRII-b), fragmento extracelular N-terminal, producido por *Escherichia coli;*

receptor II-b de baja afinidad para la región Fc de la inmunoglobulina gamma humana (IgG Fc receptor II-b, CDw32, Fc-gamma RII-b, FcRII-b, antígeno CD32)-(4-179) péptido (parte extracelular N-terminal), producido por *Escherichia coli*

Sequence / Séquence / Secuencia

```
APPKAVLKLE PQWINVLQED SVTLTCRGTH SPESDSIQWF HNGNLIPTHT 50
QPSYRFKANN NDSGEYTCQT GQTSLSDPVH LTVLSEWLVL QTPHLEFQEG 100
ETIVLRCHSW KDKPLVKVTF FQNGKSKKFS RSDPNFSIPQ ANHSHSGDYH 150
CTGNIGYTLY SSKPVTITVQ APSSSP                          176
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
26-68 107-151

vatinoxanum

vatinoxan

N-{2-[(2*R*,12b*S*)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[[1]benzofuro[2,3-*a*]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl}methanesulfonamide

vatinoxan

N-{2-[(2*R*,12b*S*)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[[1]benzofuro[2,3-*a*]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl}méthanesulfonamide

vatinoxán

N-{2-[(2*R*,12b*S*)-2'-oxo-1,3,4,6,7,12b-hexahidrospiro[[1]benzofuro[2,3-*a*]quinolizina-2,4'-imidazolidin]-3'-il]etil}metanosulfonamida

$C_{20}H_{26}N_4O_4S$



vecabrutinibum

vecabrutinib

(3*R*,3'*R*,4'*S*)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide

vécabrutinib

(3*R*,3'*R*,4'*S*)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-{[3-chloro-5-(trifluorométhyl)phényl]amino}-2-oxo-[1,3'-bipipéridine]-4'-carboxamide

vecabrutinib

(3*R*,3'*R*,4'*S*)-1'-(6-amino-5-fluoropirimidin-4-il)-3-{[3-cloro-5-(trifluorometil)fenil]amino}-2-oxo-[1,3'-bipiperidina]-4'-carboxamida

$C_{22}H_{24}ClF_3N_7O_2$



veldoreotidum

veldoreotide

$N^{4.1}$,$C^{\alpha.8}$-anhydro[*N*-(2-amino-2-oxoethyl)-4-aminobutanoyl-4-aminobutanoyl-L-phenylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-threonyl-L-phenylalanine]

veldoréotide

$N^{4.1}$,$C^{\alpha.8}$-anhydro[*N*-(2-amino-2-oxoéthyl)-4-aminobutanoyl-4-aminobutanoyl-L-phénylalanyl-L-tryptophyl-D-tryptophyl-L-lysyl-L-thréonyl-L-phénylalanine]

veldoreotida

$N^{4.1}$,$C^{\alpha.8}$-anhidro[*N*-(2-amino-2-oxoetil)-4-aminobutanoil-4-aminobutanoil-L-fenilalanil-L-triptofil-D-triptofil-L-lisil-L-treonil-L-fenilalanina]

$C_{60}H_{74}N_{12}O_{10}$



vorasidenibum

vorasidenib — 6-(6-chloropyridin-2-yl)-N^2,N^4-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidénib — 6-(6-chloropyridin-2-yl)-N^2,N^4-bis[(2*R*)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine

vorasidenib — 6-(6-cloropiridin-2-il)-N^2,N^4-bis[(2*R*)-1,1,1-trifluoropropan-2-il]-1,3,5-triazina-2,4-diamina

$C_{14}H_{13}ClF_6N_6$



zanubrutinibum

zanubrutinib — (7*S*)-2-(4-phenoxyphenyl)-7-[1-(prop-2-enoyl)piperidin-4-yl]-4,5,6,7-tetrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib — (7*S*)-2-(4-phénoxyphényl)-7-[1-(prop-2-enoyl)pipéridin-4-yl]-4,5,6,7-tétrahydropyrazolo[1,5-*a*]pyrimidine-3-carboxamide

zanubrutinib — (7*S*)-2-(4-fenoxifenil)-7-[1-(prop-2-enoil)piperidin-4-il]-4,5,6,7-tetrahidropirazolo[1,5-*a*]pirimidina-3-carboxamida

$C_{27}H_{29}N_5O_3$



zenocutuzumabum #

zenocutuzumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor tyrosine-protein kinase erbB-3, HER3) and *Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, bispecific;

	gamma1 heavy chain anti-ERBB3 (1-453) [*Homo sapiens* VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; gamma1 heavy chain anti-ERBB2 (1-450) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), hinge (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (233-230'':236-233'')-bisdisulfide
zénocutuzumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB3 (récepteur à activité tyrosine kinase erbB-3, HER3) et *Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé, bispécifique; chaîne lourde gamma1 anti-ERBB3 (1-453) [*Homo sapiens* VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), charnière (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; chaîne lourde gamma1 anti-ERBB2 (1-450) [VH humanisé (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), charnière (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dimère (233-230'':236-233'')-bisdisulfure
zenocutuzumab	inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB3 (receptor de la actividad tirosina kinasa erbB-3, HER3) y *Homo sapiens* ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado, biespecífico; cadena pesada gamma1 anti-ERBB3 (1-453) [*Homo sapiens* VH (IGHV1-2*02 (100.00%) -(IGHD) -IGHJ4*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), bisagra (223-237), CH2 (238-347), CH3 L7>K (358), E12 (363), M14 (365), T22>K (373) (348-452), CHS K>del (453)) (125-453)], (227-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; cadena pesada gamma1 anti-ERBB2 (1-450) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (218) (122-219), bisagra (220-234), CH2 (235-344), CH3 L7>D (355), E12 (360), M14 (362), L24>E (372) (345-449), CHS K>del (450)) (122-450)] (224-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (100.00%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 A45.1 (153), V101 (191) (108'-214')]; dímero (233-230'':236-233'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB3)

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYYMHWVRQA PGQGLEWMGW  50
INPNSGGTNY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARDH 100
GSRHFWSYWG FDYWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK RVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTKPP SREEMTKNQV SLKCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPG                                                     453
```

Heavy chain / Chaîne lourde / Cadena pesada (anti-ERBB2)

```
QVQLVQSGAE VKKPGASVKL SCKASGYTFT AYYINWVRQA PGQGLEWIGR  50
IYPGSGYTSY AQKFQGRATL TADESTSTAY MELSSLRSED TAVYFCARPP 100
VYYDSAWFAY WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTDPPSRE EMTKNQVSLT CEVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVI ITCRASQSIS SYLNWYQQKP GKAPKLLIYA  50
ASSLQSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 151-207 268-328 374-432
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L (C23-C104) 23'-88' 134'-194'
23"'-88"' 134"'-194"'
Inter-H-L (h 5-CL 126) 227-214' 224"-214"'
Inter-H-H (h 11, h 14) 233-230" 236-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
304, 301"
Defucosylated (≥ 90%) complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes défucosylés (≥ 90%) / glicanos de tipo CHO biantenarios complejos defucosilados (≥ 90%)

zolbetuximabum #

zolbetuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CLDN18 (claudin 18, claudin-18, SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], chimeric monoclonal antibody;
gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) -(IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), hinge (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227"':230-230"')-bisdisulfide

zolbétuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CLDN18 (claudine 18, claudine-18, SFTPJ, surfactant associé à la protéine J) isoforme 2, domaine extracellulaire 1 (EC1)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) -(IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), charnière (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')]; dimère (227-227"':230-230"')-bisdisulfure

zolbetuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CLDN18 (claudina 18, claudina-18, SFTPJ, surfactante asociado a la proteína J) isoforma 2, dominio extracelular 1 (EC1)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-61*01 (92.90%) -(IGHD) -IGHJ2*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (215) (119-216), bisagra (217-231), CH2 (232-341), CH3 E12 (357), M14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV8-19*01 (100.00%) -IGKJ4*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01, Km3 A45.1 (159), V101 (197) (114'-220')];
dímero (227-227'':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQPGAE LVRPGASVKL SCKASGYTFT SYWINWVKQR PGQGLEWIGN  50
IYPSDSYTNY NQKFKDKATL TVDKSSSTAY MQLSSPTSED SAVYYCTRSW 100
RGNSFDYWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPSS LTVTAGEKVT MSCKSSQSLL NSGNQKNYLT WYQQKPGQPP  50
KLLIYWASTR ESGVPDRFTG SGSGTDFTLT ISSVQAEDLA VYYCQNDYSY 100
PFTFGSGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                   220
```

Post-translational modifications
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-94' 140'-200'
23'"-94'" 140'"-200'"
Inter-H-L (h 5-CL 126) 221-220' 221"-220'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaire complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/

AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Nonproprietary Names (Rec. INN): List 47
Dénominations communes internationales recommandées (DCI Rec.): Liste 47
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 47
(WHO Drug Information, Vol. 16, No 1, 2002)

p. 84 **alicaforsenum**

alicaforsen — *replace the chemical name and the molecular formula by the following ones*

alicaforsen — *remplacer le nom chimique et la formule moléculaire brute par les suivants*

alicaforsén — *sustitúyase el nombre químico y la fórmula molecular por los siguientes*

all-P-(R)-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxyadenosine

tout-P-(R)-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'_5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-désoxy-*P*-thiocytidylyl-(3'→5')-2'-désoxyadénosine

todo-P-(R)-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'_5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxiadenosina

$C_{192}H_{244}N_{75}O_{98}P_{19}S_{19}$

Recommended International Nonproprietary Names (Rec. INN): List 71
Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No 1, 2014)

p. 101 **patisiranum**

patisiran	*replace the molecular formula by the following one*
patisiran	*remplacer la formule moléculaire brute par la suivante*
patisirán	*sustitúyase la fórmula molecular por la siguiente*

$C_{412}H_{520}N_{148}O_{290}P_{40}$

Recommended International Nonproprietary Names (Rec. INN): List 75
Dénominations communes internationales recommandées (DCI Rec.): Liste 75
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 75
(WHO Drug Information, Vol. 30, No 1, 2016)

p. 105 **cenerimodum #**

cenerimod	*replace the structure by the following one*
cénérimod	*remplacer la structure par la suivante*
cenerimod	*sustitúyase la estructura por la siguiente*



Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.